Adult Antiretroviral Guidelines

US DHHS Guidelines with Australian Commentary

PI Drug interactions

Table of Contents

Adult Guidelines > > Drug-Drug Interactions > PI Drug interactions
Sections
Table of Contents

Drug Interactions Between Protease Inhibitors and Other Drugs

DHHS Last Updated: September 2024Australian Commentary Last Updated: December 2024

Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs

This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. The term “PI” refers to atazanavir (ATV) or darunavir (DRV) boosted with either ritonavir (RTV or r) or cobicistat (COBI or c). This table does not include interactions for unboosted ATV, fosamprenavir (FPV), l opinavir (LPV), nelfinavir (NFV), or tipranavir (TPV). For information regarding interactions between PIs and other ARV drugs, including dosing recommendations, refer to Tables 24c, 25a, and 25b.

Recommendations for managing a particular drug interactions may differ depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or whether a new concomitant medication is being initiated in a patient on a stable ARV regimen. The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. In cases where an interacting drug needs to be replaced with an alternative, providers should exercise their clinical judgment to select the most appropriate alternative medication.

Note: Unboosted ATV, FPV, LPV/r, NFV, and TPV are no longer commonly used in clinical practice i n the United States and are not included in this table. Please refer to the U.S. Food and Drug Administration product labels for information regarding drug interactions between these PIs and concomitant medications. Information regarding these agents may also be found in archived versions of this guideline.

Concomitant Drug
PI
Effect on PI and/or Concomitant Drug Concentrations
Dosing Recommendations and Clinical Comments
Acid Reducers
AntacidsATV (unboosted), ATV/c, ATV/rWhen Given Simultaneously
  • ↓ ATV expected
Administer ATV at least 2 hours before or 2 hours after antacids or buffered medications.
H2 Receptor AntagonistsATV/c, ATV/r↓ ATV expectedH2RA dose should not exceed a dose equivalent to famotidine 40 mg twice daily in ART-naive patients or famotidine 20 mg twice daily in ART-experienced patients.

Give ATV 300 mg (plus COBI 150 mg or RTV 100 mg) with food simultaneously with and/or ≥10 hours after the dose of H2RA.

If using TDF and H2RA in ART-experienced patients, administer ATV 400 mg plus RTV 100 mg with food simultaneously with and/or ≥10 hours after the dose of H2RA.

Do not coadminister ATV/c with TDF and H2RA in ART-experienced patients.
DRV/c, DRV/r, LPV/rWith Ranitidine
  • ↔ DRV/r
No dose adjustment needed.
Proton Pump InhibitorsATV/c, ATV/rWith Omeprazole 40 mg
  • ATV AUC ↓ 76%

When Omeprazole 20 mg Is Given 12 Hours before ATV/c or ATV/r
  • ATV AUC ↓ 42%
PPI dose should not exceed a dose equivalent to omeprazole 20 mg daily in PI-naive patients.

PPIs should be administered at least 12 hours before ATV/c or ATV/r.
Do not coadminister in PI-experienced patients.
DRV/c, LPV/r↔ PI expectedNo dose adjustment needed.
DRV/r↔ DRV/r
Omeprazole AUC ↓ 42%
Consider alternative ARV or acid reducer. If coadministered, monitor for omeprazole efficacy. If the patient does not experience symptomatic relief, increase the dose to no more than omeprazole 40 mg daily.
Alpha-Adrenergic Antagonists for Benign Prostatic Hyperplasia
AlfuzosinATV/c, ATV/r, DRV/c, DRV/r↑ alfuzosin expectedContraindicated.
DoxazosinATV/c, ATV/r, DRV/c, DRV/r↑ doxazosin possibleInitiate doxazosin at lowest dose and titrate. Monitor blood pressure. Dose reduction may be necessary.
TamsulosinATV/c, ATV/r, DRV/c, DRV/r↑ tamsulosin expectedDo not coadminister unless benefits outweigh risks. If coadministered, monitor blood pressure.
TerazosinATV/c, ATV/r, DRV/c, DRV/r↔ or ↑ terazosin possibleInitiate terazosin at lowest dose and titrate. Monitor blood pressure. Dose reduction may be necessary.
SilodosinATV/c, ATV/r, DRV/c, DRV/r↑ silodosin expectedContraindicated.
Antibacterials—Antimycobacterials
BedaquilineAll PIsWith LPV/r
  • Bedaquiline AUC ↑ 1.9-fold

With Other PI/r, ATV/c, or DRV/c
  • ↑ bedaquiline possible
Do not coadminister unless benefits outweigh risks. If coadministered, consider therapeutic drug monitoring and monitor for bedaquiline-related adverse effects, including hepatotoxicity and QTc prolongation.
RifabutinATV/rCompared With Rifabutin (300 mg Once Daily) Alone, Rifabutin (150 mg Once Daily) Plus ATV/r
  • Rifabutin AUC ↑ 110% and metabolite AUC ↑ 2,101%
Recommended dose is rifabutin 150 mg once daily.

Monitor for antimycobacterial activity and consider therapeutic drug monitoring. Monitor for rifabutin-related adverse events, including neutropenia and uveitis.

PK data in this table are results from healthy volunteer studies. Lower rifabutin exposure has been reported in patients with HIV than in healthy study participants.
DRV/rCompared With Rifabutin (300 mg Once Daily) Alone, Rifabutin (150 mg Every Other Day) Plus DRV/r
  • ↔ rifabutin AUC and metabolite AUC ↑ 881%
ATV/c, DRV/c↑ rifabutin expected
↓ COBI expected
Do not coadminister.
RifampinATV/c, ATV/r, DRV/c, DRV/r↓ PI concentration by >75%Contraindicated. Increasing the dose of RTV does not overcome this interaction and may increase hepatotoxicity. Increasing the COBI dose is not recommended. Consider rifabutin if a rifamycin is indicated.
RifapentineATV/c, ATV/r, DRV/c, DRV/r Daily and Weekly Dosing
↓ PI expected
Do not coadminister.
Antibacterials—Macrolides
AzithromycinATV (unboosted), ATV/c, ATV/r↑ azithromycin possibleNo dose adjustment needed.
DRV/c, DRV/r↔ azithromycin expectedNo dose adjustment needed.
ClarithromycinATV/c, ATV/r, DRV/c↑ clarithromycin expected
↑ ATV/r and PI/c expected
Consider alternative ARV or azithromycin.
DRV/r, LPV/rDRV/r ↑ clarithromycin AUC 57%
LPV/r ↑ clarithromycin expected
RTV 500 mg twice daily ↑ clarithromycin 77%
Consider alternative ARV or azithromycin.

If use of clarithromycin is necessary in a patient with impaired renal function, reduce clarithromycin dose by 50% in patients with CrCl 30 to 60 mL/min. In patients with CrCl <30 mL/min, reduce clarithromycin dose by 75%.
Monitor for clarithromycin-related adverse events, including QTc prolongation.
ErythromycinATV/c, ATV/r, DRV/c, DRV/r↑ erythromycin expected
↑ PIs expected
Consider alternative ARV or use azithromycin.
Anticoagulants
ApixabanATV/c, ATV/r, DRV/c, DRV/r↑ apixaban expectedDo not coadminister in patients who require apixaban 2.5 mg twice daily.
In Patients Requiring Apixaban 5 mg or 10 mg Twice Daily
  • Reduce apixaban dose by 50%.

DabigatranATV/c, ATV/rWith COBI 150 mg Alone
  • Dabigatran AUC ↑ 110% to 127%

With ATV/r
  • ↑ dabigatran expected
Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation in Adult Patients

  • CrCl >30 mL/min: no dose adjustment needed

  • CrCl ≤30 mL/min: do not coadminister.


Treatment and Reduction in the Risk of Recurrence of DVT and PE or Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients

  • CrCl ≥50 mL/min: no dose adjustment needed

  • CrCl <50 mL/min: do not coadminister.
DRV/c, DRV/rWith DRV/c
  • Single dose DRV/c: dabigatran AUC ↑ 164%
  • After 14 days of DRV/c: dabigatran AUC ↑ 88%

With DRV/r
  • Single dose DRV/r: dabigatran AUC ↑ 72%
  • After 14 days of daily DRV/r: dabigatran AUC ↑ 18%
EdoxabanATV/r, ATV/c↑ edoxaban expectedStroke Prevention in Nonvalvular Atrial Fibrillation Indication
  • No dose adjustment needed.

Deep Venous Thrombosis and Pulmonary Embolism Indication
  • Administer edoxaban 30 mg once daily.

DRV/r↑ edoxaban expectedStroke Prevention in Nonvalvular Atrial Fibrillation Indication
  • No dose adjustment needed.

Deep Venous Thrombosis and Pulmonary Embolism Indication
  • No dose adjustment needed

RivaroxabanATV/c, ATV/r, DRV/c, DRV/r↑ rivaroxaban possibleDo not coadminister.
WarfarinATV/c, DRV/c↑ warfarin possibleMonitor INR closely when stopping or starting PI/c or PI/r and adjust warfarin dose accordingly.

If switching between RTV and COBI, the effect of COBI on warfarin is not expected to be equivalent to RTV’s effect on warfarin.
ATV/r, DRV/r↓ warfarin possible
Antidepressants, Anxiolytics, and Antipsychotics
Also see the Sedative/Hypnotics section below
Antidepressants, Anxiolytics
BupropionATV/r, DRV/r↓ bupropion possibleTitrate bupropion dose based on clinical response.
ATV/c, DRV/c↔ bupropion expectedNo dose adjustment needed.
BuspironeATV/c, ATV/r, DRV/c, DRV/r↑ buspirone expectedAdminister lowest dose of buspirone with caution and titrate buspirone dose based on clinical response. Dose reduction may be necessary. Monitor for buspirone-related adverse events.
DesvenlafaxineATV/c, ATV/r, DRV/c, DRV/r↑ desvenlafaxine expectedNo dose adjustment needed.
DuloxetineATV/c, ATV/r, DRV/c, DRV/r↑ duloxetine expectedNo dose adjustment needed.
MirtazapineATV/c, ATV/r, DRV/c, DRV/r↑ mirtazapine expectedMonitor for mirtazapine-related adverse events. Mirtazapine dose reduction may be necessary.
NefazodoneATV/c, ATV/r, DRV/c, DRV/r↑ nefazodone expected
↑ PI possible
Monitor for nefazodone-related adverse events and PI tolerability.
Selective Serotonin Reuptake Inhibitors
(e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vortioxetine)
DRV/rParoxetine AUC ↓ 39%
Sertraline AUC ↓ 49%
Titrate SSRI dose based on clinical response.
ATV/c, ATV/r, DRV/c↑ or ↓ SSRI possibleTitrate SSRI dose using the lowest available initial or maintenance dose.
TrazodoneATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily (for 2 days)
  • Trazodone ↑ AUC 240%
Administer lowest dose of trazodone and monitor for CNS and CV adverse events.
Tricyclic Antidepressants
Amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine
ATV/c, ATV/r, DRV/c, DRV/r↑ TCA expectedAdminister lowest possible TCA dose and titrate based on clinical assessment and/or drug concentrations. Monitor for TCA-related adverse events.
VenlafaxineATV/c, ATV/r, DRV/c, DRV/r↑ venlafaxine and O-desmethylvenlafaxine expectedMonitor for venlafaxine-related adverse events. Consider venlafaxine dose reduction.
Antipsychotics
AripiprazoleATV/c, ATV/r, DRV/c, DRV/r↑ aripiprazole expectedAdminister 25% of the usual aripiprazole dose. Titrate dose based on clinical monitoring for effectiveness/adverse events. Refer to aripiprazole label for doses to use in patients who have major depressive disorder or who are known to be CYP2D6-poor metabolizers.
BrexpiprazoleATV/c, ATV/r, DRV/c, DRV/r↑ brexpiprazole expectedAdminister 25% of the usual brexpiprazole dose. Titrate the dose based on clinical monitoring for efficacy/adverse events. Refer to brexpiprazole label for doses to use in patients who have major depressive disorder or who are known to be CYP2D6 poor metabolizers.
CariprazineATV/c, ATV/r, DRV/c, DRV/r↑ cariprazine expectedStarting Cariprazine in a Patient Who Is Already Receiving a PI
  • Administer cariprazine 1.5 mg on Day 1 and Day 3, with no dose given on Day 2. From Day 4 onward, administer cariprazine 1.5 mg daily. Dose can be increased to a maximum of cariprazine 3 mg daily. If the PI is withdrawn, cariprazine dose may need to be increased.

Starting a PI in a Patient Who Is Already Receiving Cariprazine
  • For patients receiving cariprazine 3 mg or cariprazine 6 mg daily, reduce the dose by half. For patients taking cariprazine 4.5 mg daily, the dose should be reduced to cariprazine 1.5 mg or cariprazine 3 mg daily. For patients taking cariprazine 1.5 mg daily, change to cariprazine 1.5 mg every other day. If PI is withdrawn, the cariprazine dose may need to be increased.
IloperidoneATV/c, ATV/r, DRV/c, DRV/r↑ iloperidone expectedDecrease iloperidone dose by 50%.
LumateperoneATV/c, ATV/r, DRV/c, DRV/r↑ lumateperone expectedDo not coadminister.
LurasidoneATV/c, ATV/r, DRV/c, DRV/r↑ lurasidone expectedContraindicated.
Olanzapine, Olanzapine/SamidorphanATV/c, DRV/c↔ olanzapine expected

↑ samidorphan possible
No dose adjustment needed.
ATV/r, DRV/r↓ olanzapine possibleMonitor for therapeutic effectiveness of olanzapine.
Other Antipsychotics
CYP3A4 and/or CYP2D6 substrates (e.g., clozapine, perphenazine, risperidone, thioridazine)
ATV/c, ATV/r, DRV/c, DRV/r↑ antipsychotic possibleTitrate the antipsychotic dose using the lowest initial dose or adjust the maintenance dose accordingly. Monitor for adverse events, including QTc prolongation.
PimavanserinATV/c, ATV/r, DRV/c, DRV/r↑ pimavanserin expectedReduce pimavanserin dose to 10 mg once daily.
PimozideATV/c, ATV/r, DRV/c, DRV/r↑ pimozide expectedContraindicated.
QuetiapineATV/c, ATV/r, DRV/c, DRV/r↑ quetiapine expectedStarting Quetiapine in a Patient Receiving a PI
  • Initiate quetiapine at the lowest dose and titrate up as needed. Monitor for quetiapine effectiveness and adverse events, including QTc prolongation.

  • Starting a PI in a Patient Receiving a Stable Dose of Quetiapine
    • Consider alternative ARV. If coadministered, reduce quetiapine dose to 1/6 of the current dose. Closely monitor for quetiapine effectiveness and adverse events, including QTc prolongation.
    ZiprasidoneATV/c, ATV/r, DRV/c, DRV/r↑ ziprasidone expectedMonitor for ziprasidone-related adverse events, including QTc prolongation.
    Antimigraine
    Ergot DerivativesATV/c, ATV/r, DRV/c, DRV/r↑ dihydroergotamine, ergotamine, and methylergonovine expectedContraindicated.
    Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
    AtogepantATV/c, ATV/r, DRV/c, DRV/r↑ atogepant expectedChronic migraine: Do not coadminister.

    Episodic migraine: Administer atogepant at a dose of 10 mg once daily.
    RimegepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedDo not coadminister.
    UbrogepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedContraindicated.
    ZavegepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedDo not coadminister.
    DRV/r↔ zavegepant expectedNo dose adjustment needed
    Serotonin 5-HT1B, 1D Receptor Agonists
    AlmotriptanATV/c, ATV/r, DRV/c, DRV/r↑ almotriptan expected No dose adjustment needed
    EletriptanATV/c, ATV/r, DRV/c, DRV/r↑ eletriptan expectedContraindicated.
    Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan ZolmitriptanATV/c, ATV/r, DRV/c, DRV/r↔ triptan expectedNo dose adjustment needed
    Antifungals
    FluconazoleATV/c, ATV/r, DRV/c, DRV/r↔ PI expected
    ↔ fluconazole expected
    No dose adjustment needed.
    IsavuconazoleATV/c, DRV/c↑ isavuconazole expected

    ↓ PI possible
    Contraindicated.
    ATV/r, DRV/r↑ isavuconazole expected

    ↓ PI possible
    If coadministered, monitor isavuconazole concentrations and monitor for isavuconazole-related adverse events. Monitor for PI tolerability.
    IbrexafungerpATV/c, ATV/r, DRV/c, DRV/r↑ ibrexafungerp expectedReduce ibrexafungerp dose to 150 mg twice daily.
    ItraconazoleATV/c, ATV/r, DRV/c, DRV/r↑ itraconazole expected
    ↑ PI expected
    Itraconazole doses >200 mg/day are not recommended unless dosing is guided by itraconazole concentrations.
    PosaconazoleATV/rATV AUC ↑ 146%
    ↑ posaconazole possible
    If coadministered, monitor posaconazole concentrations and monitor for posaconazole-related or PI-related adverse events.
    ATV/c, DRV/c, DRV/r↑ PI expected
    ↑ posaconazole possible
    VoriconazoleATV/c, DRV/cNo data
    ATV/r, DRV/rRTV 100 mg twice daily ↓ voriconazole AUC 39%Do not coadminister voriconazole and RTV or COBI unless benefits outweigh risks. If coadministered, monitor voriconazole concentration and adjust dose accordingly.
    Antimalarials
    Artemether/LumefantrineATV/c, DRV/c↑ lumefantrine expected

    ↑ artemether possible
    Clinical significance is unknown. If coadministered, monitor closely for antimalarial efficacy and lumefantrine-related adverse events, including QTc prolongation.
    DRV/rArtemether AUC ↓ 16%
    DHAa AUC ↓ 18%
    Lumefantrine AUC ↑ 175%
    ↔ DRV
    ArtesunateATV/c ↑ DHAa possibleMonitor for artesunate-related adverse effects.
    DRV/c↓ DHAa possibleNo dose adjustment needed
    ATV/r, DRV/r↓ DHAa possibleMonitor for artesunate-related adverse effects.
    Atovaquone/ProguanilATV/r, DRV/rWith ATV/r
    • Atovaquone AUC ↓ 46%
    • Proguanil AUC ↓ 41%

    With LPV/r
    • Atovaquone AUC ↓ 74%
    • Proguanil AUC ↓ 38%
    Clinical significance is unknown. Consider alternative ARV or malaria prophylaxis.
    ATV/c, DRV/c↔ atovaquone/proguanil expectedNo dose adjustment needed
    MefloquineAll PIsWith RTV 200 mg Twice Daily
    • RTV AUC ↓ 31% and Cmin ↓ 43%
    • ↔ mefloquine

    With ATV (Unboosted), PI/c, or PI/r
    • No data
    • ↑ mefloquine possible
    Clinical significance is unknown. Consider alternative ARV or antimalarial drug. If coadministered, monitor for mefloquine-related adverse events, including psychiatric symptoms and QTc prolongation. Monitor virologic response.
    Antiplatelets
    ClopidogrelATV/c, ATV/r, DRV/c, DRV/rClopidogrel active metabolite AUC ↓ 69% in people with HIV compared to healthy volunteers without HIV. Impaired platelet inhibition observed in people with HIV.Do not coadminister.
    PrasugrelATV/c, ATV/r, DRV/c, DRV/rPrasugrel active metabolite AUC ↓ 52% in people with HIV compared to healthy volunteers without HIV. Adequate platelet inhibition observed in people with HIV.No dose adjustment needed.
    TicagrelorATV/c, ATV/r, DRV/c, DRV/r↑ ticagrelor expectedDo not coadminister.
    VorapaxarATV/c, ATV/r, DRV/c, DRV/r↑ vorapaxar expectedDo not coadminister.
    Antipneumocystis and Antitoxoplasmosis Drug
    Atovaquone
    Oral suspension
    ATV/r↔ atovaquoneNo dose adjustment needed.
    ATV/c, DRV/c, DRV/r↔ atovaquone expectedNo dose adjustment needed.
    Antiseizure
    CarbamazepineATV/r↑ carbamazepine possible
    May ↓ PI concentrations substantially
    Consider alternative ARV or anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assess virologic response. Carbamazepine dose reduction may be necessary.
    Do not coadminister with LPV/r once daily.
    DRV/rCarbamazepine AUC ↑ 45%
    ↔ DRV
    Monitor anticonvulsant concentration and adjust dose accordingly.
    ATV/c, DRV/c↑ carbamazepine possible
    ↓ COBI expected
    ↓ PI expected
    Contraindicated.
    EslicarbazepineATV/c, ATV/r, DRV/c, DRV/r↓ PI possibleConsider alternative ARV or anticonvulsant. If coadministration is necessary, monitor for virologic response. Consider monitoring anticonvulsant and PI concentrations.
    EthosuximideATV/c, ATV/r, DRV/c, DRV/r↑ ethosuximide possibleMonitor for ethosuximide-related adverse events.
    LamotrigineATV/rLamotrigine AUC ↓ 32%A dose increase of lamotrigine may be needed; monitor lamotrigine concentration or consider alternative ARV or anticonvulsant.
    DRV/r↓ lamotrigine possible
    ATV/cNo dataMonitor anticonvulsant concentration and adjust dose accordingly.
    DRV/c↔ lamotrigine expectedNo dose adjustment needed.
    OxcarbazepineATV/c, ATV/r, DRV/c, DRV/r↓ PI possibleConsider alternative ARV or anticonvulsant. If coadministration necessary, monitor for virologic response. Consider monitoring anticonvulsant and PI concentrations.
    PhenobarbitalATV/r, DRV/r↓ phenobarbital possible
    ↓ PI possible
    Consider alternative anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assessing virologic response.
    ATV/c, DRV/c↓ COBI expected

    ↓ PI expected
    Contraindicated.
    PhenytoinATV/r, DRV/r↓ phenytoin possible

    ↓ PI possible
    Consider alternative anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assessing virologic response.
    ATV/c, DRV/c↓ COBI expected

    ↓ PI expected
    Contraindicated.
    PrimidoneATV/c, ATV/r, DRV/c, DRV/r↓ PI expectedDo not coadminister.
    Valproic AcidATV/c, ATV/r, DRV/c, DRV/r↓ or ↔ VPA possible
    LPV AUC ↑ 38%
    No data for other PIs
    Monitor VPA concentrations and monitor for PI tolerability.
    Antivirals—Hepatitis C
    Elbasvir/GrazoprevirATV/rElbasvir AUC ↑ 4.8-fold
    Grazoprevir AUC ↑ 10.6-fold
    Elbasvir ↔ ATV
    Grazoprevir ↑ ATV AUC 43%
    Contraindicated.
    May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.
    DRV/rElbasvir AUC ↑ 66%
    Grazoprevir AUC ↑ 7.5-fold
    ↔ DRV
    ATV/c, DRV/c↑ grazoprevir expected
    Glecaprevir/PibrentasvirATV/c, ATV/rWith (ATV 300 mg plus RTV 100 mg) Once Daily
    • Glecaprevir AUC ↑ 6.5-fold
    • Pibrentasvir AUC ↑ 64%
    Contraindicated.
    DRV/c, DRV/rWith (DRV 800 mg plus RTV 100 mg) Once Daily
    • Glecaprevir AUC ↑ 5-fold
    • ↔ pibrentasvir
    Do not coadminister..
    Ledipasvir/SofosbuvirATV/rATV AUC ↑ 33%
    Ledipasvir AUC ↑ 113%
    ↔ sofosbuvir
    No dose adjustment needed.
    Coadministration of ledipasvir/sofosbuvir with TDF and a PI/r results in increased exposure to TDF. The safety of the increased TDF exposure has not been established. Consider alternative HCV or ARV drugs to avoid increased risk of TDF toxicities. If coadministration is necessary, monitor for TDF-related adverse events.
    ATV/c, DRV/c, DRV/rATV (unboosted), ATV/c, DRV/c, DRV/r, LPV/r
    Sofosbuvir/VelpatasvirATV/r↔ ATV/r

    ↔ sofosbuvir

    Velpatasvir AUC ↑ 2.4-fold
    No dose adjustment needed.
    DRV/r↔ DRV/r
    Sofosbuvir AUC ↓ 28%
    ↔ velpatasvir
    No dose adjustment needed.
    ATV/c, DRV/c↔ sofosbuvir and velpatasvir expectedNo dose adjustment needed.
    Sofosbuvir/Velpatasvir/VoxilaprevirATV/c, ATV/rWith ATV/r
    • Voxilaprevir AUC ↑ 4.3-fold
    • Velpatasvir AUC ↑ 93%
    • Sofosbuvir AUC ↑ 40%
    Do not coadminister.
    DRV/c, DRV/rWith DRV/r
    • Voxilaprevir AUC ↑ 2.4-fold
    • ↔ DRV/r, velpatasvir, and sofosbuvir
    No dose adjustment needed.
    Antivirals—Miscellaneous (e.g., for CMV, Mpox)
    BrincidofovirATV/c, ATV/r, DRV/c, DRV/r↑ brincidofovir possibleGive PI dose at least 3 hours after administering brincidofovir and monitor for brincidofovir-related adverse events (i.e., elevations in ALT/AST and bilirubin and GI adverse events).
    CidofovirATV/c, ATV/r, DRV/c, DRV/r↔ cidofovirNo dose adjustment needed.
    TecovirimatATV/c, ATV/r, DRV/c, DRV/r↔ tecovirimatNo dose adjustment needed.
    Antivirals—SARS-CoV-2
    MolnupiravirATV/c, ATV/r, DRV/c, DRV/r↔ molnupiravirNo dose adjustment needed
    RemdesivirATV/c, ATV/r, DRV/c, DRV/r↔ remdesivirNo dose adjustment needed
    Ritonavir-Boosted NirmatrelvirATV/c, ATV/r, DRV/c, DRV/r↑ PI expected

    ↑ ritonavir-boosted nirmatrelvir expected
    No dose adjustment needed. Monitor for increased ritonavir-boosted nirmatrelvir and PI-related adverse events.
    Beta-Agonists, Long-Acting Inhaled
    Arformoterol, FormoterolATV/c, ATV/r↑ arformoterol possibleNo dose adjustment needed.
    DRV/c, DRV/r, LPV/r↔ arformoterol expectedNo dose adjustment needed.
    IndacaterolATV/c, ATV/r, DRV/c, DRV/rWith RTV 300 mg Twice Daily
    • Indacaterol AUC ↑ 1.7-fold
    No dose adjustment needed in patients receiving indacaterol 75 mcg daily.
    OlodaterolATV/c, ATV/r, DRV/c, DRV/r↑ olodaterol expectedNo dose adjustment needed.
    SalmeterolATV/c, ATV/r, DRV/c, DRV/r↑ salmeterol possibleDo not coadminister, due to potential increased risk of salmeterol-related CV events.
    Cardiac Medications
    Antiarrhythmics
    AmiodaroneATV/r↑ amiodarone possible
    ↑ PI possible
    Contraindicated.
    ATV/c, DRV/c, DRV/r↑ amiodarone possible
    ↑ PI possible
    Do not coadminister unless the benefits outweigh the risks. If coadministered, monitor for amiodarone-related adverse events and consider monitoring ECG and amiodarone drug concentration.
    DigoxinATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily ↑ digoxin AUC 29% and ↑ half-life 43%

    DRV/r ↑ digoxin AUC 36%

    COBI ↑ digoxin Cmax 41% and ↔ AUC
    RTV 200 mg twice daily ↑ digoxin AUC 29% and ↑ half-life 43%

    DRV/r ↑ digoxin AUC 36%

    COBI ↑ digoxin Cmax 41% and ↔ AUC
    DisopyramideATV/c, ATV/r, DRV/c, DRV/r↑ disopyramide possibleDo not coadminister.
    DofetilideATV/c, ATV/r, DRV/c, DRV/r↑ dofetilide possibleDo not coadminister.
    DronedaroneATV/c, ATV/r, DRV/c, DRV/r↑ dronedarone possibleContraindicated.
    FlecainideATV/c, ATV/r, DRV/c, DRV/r↑ flecainide possibleConsider alternative ARV or antiarrhythmic. If coadministered, monitor flecainide concentrations and for antiarrhythmic-related adverse events.
    LidocaineATV/c, ATV/r, DRV/c, DRV/r↑ lidocaine possibleConsider alternative ARV or antiarrhythmic. If coadministered, monitor lidocaine concentrations and for antiarrhythmic-related adverse events.
    MexiletineATV/c, ATV/r, DRV/c, DRV/r↑ mexiletine possible Consider alternative ARV or antiarrhythmic. If coadministered, monitor mexiletine concentrations and for antiarrhythmic-related adverse events.
    PropafenoneATV/c, ATV/r, DRV/c, DRV/r↑ propafenone possibleDo not coadminister.
    QuinidineATV/r↑ quinidine expectedContraindicated.
    ATV/c, DRV/c, DRV/r↑ quinidine possibleDo not coadminister.
    SotalolATV/c, ATV/r, DRV/c, DRV/r↔ sotalol expectedNo dose adjustment needed
    Beta-Blockers
    Atenolol, LabetalolATV/c, ATV/r, DRV/c, DRV/r↑ beta-blockers possibleNo dose adjustment needed
    Bisoprolol, Carvedilol, Metoprolol, NebivololATV/c, ATV/r, DRV/c, DRV/r↑ beta-blockers possibleMay need to decrease beta-blocker dose; adjust dose based on clinical response.

    Consider using beta-blockers that are not metabolized by CYP2D6 enzymes (e.g., atenolol, labetalol, nadolol).
    Calcium Channel Blockers
    Amlodipine, Felodipine, Nifedipine, VerapamilATV/c, ATV/r, DRV/c, DRV/r↑ CCB possibleTitrate CCB dose and monitor closely. ECG monitoring is recommended when CCB is used with ATV.
    Amlodipine, Felodipine, Nifedipine, VerapamilATV/c, ATV/r, DRV/c, DRV/r↑ CCB possibleTitrate CCB dose and monitor closely. ECG monitoring is recommended when CCB is used with ATV.
    DiltiazemATV/c, ATV/rUnboosted ATV ↑ diltiazem AUC 125%

    Greater ↑ of diltiazem AUC is likely with ATV/c or ATV/r
    Decrease diltiazem dose by at least 50%. If starting diltiazem, start with the lowest dose and titrate according to clinical response and adverse events. ECG monitoring is recommended.
    DRV/c, DRV/r↑ diltiazem possibleTitrate diltiazem dose according to clinical response and adverse events.
    Cardiac—Other
    BosentanATV/c, ATV/r, DRV/c, DRV/rWith LPV/r
    • ↑ bosentan 48-fold (Day 4) and ↑ 5-fold (Day 10)

    With other PI
    ↑ bosentan expected
    With ATV (unboosted)
    ↓ ATV expected
    Do not coadminister bosentan and unboosted ATV.
    In Patients on a PI (Other than Unboosted ATV) >10 Days
    • Start bosentan at 62.5 mg once daily or every other day

    In Patients on Bosentan Who Require a PI (Other Than Unboosted ATV)
    • Stop bosentan ≥36 hours before PI initiation and restart bosentan 10 days after PI initiation at 62.5 mg once daily or every other day.

    When Switching Between COBI and RTV
    • Maintain the same bosentan dose.

    EplerenoneATV/c, ATV/r, DRV/c, DRV/r↑ eplerenone expectedContraindicated.
    IvabradineATV/c, ATV/r, DRV/c, DRV/r↑ ranolazine expectedContraindicated.
    MavacamtenATV/c, ATV/r, DRV/c, DRV/r↑ mavacamten expectedContraindicated.
    RanolazineATV/c, ATV/r, DRV/c, DRV/r↑ ranolazine possibleContraindicated.
    Corticosteroids
    Beclomethasone
    Inhaled or intranasal
    DRV/r↔ 17-BMP (active metabolite) AUC
    RTV 100 mg twice daily ↑ 17-BMP AUC 2-fold
    No dose adjustment needed.
    All PIs except DRV/r↔ 17-BMP expectedNo dose adjustment needed.
    Budesonide, Ciclesonide, Fluticasone, Mometasone
    Inhaled or intranasal
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible
    RTV 100 mg twice daily ↑ fluticasone AUC 350-fold
    Do not coadminister unless the potential benefits of inhaled or intranasal corticosteroid outweigh the risks of adverse events associated with corticosteroids. Coadministration can result in adrenal insufficiency and Cushing’s syndrome. Consider alternative inhaled/intranasal corticosteroid (e.g., beclomethasone).
    Betamethasone, Budesonide
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible

    ↓ PI possible
    Do not coadminister unless the potential benefits of systemic corticosteroid outweigh the risks of adverse events associated with systemic corticosteroids. Coadministration can result in adrenal insufficiency and Cushing’s syndrome.
    Dexamethasone
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible
    ↓ PI possible
    Consider alternative corticosteroid for long-term use. If coadministration is necessary, monitor virologic response to ART.
    Prednisone, Prednisolone
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ prednisolone possibleCoadministration may be considered if the potential benefits outweigh the risks of adverse events associated with systemic corticosteroids. If coadministered, monitor for adrenal insufficiency, Cushing’s syndrome, and other corticosteroid-related adverse events.
    Betamethasone, Methylprednisolone, Triamcinolone
    Local injections, including intra-articular, epidural, or intra-orbital
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids expectedDo not coadminister. Coadministration can result in adrenal insufficiency and Cushing’s syndrome.
    Glucose-Lowering
    CanagliflozinATV/c, DRV/c↔ canagliflozinNo dose adjustment needed.
    ATV/r, DRV/r↓ canagliflozin expectedIf a patient is already tolerating canagliflozin 100 mg daily, increase canagliflozin dose to 200 mg daily.
    If a patient is already tolerating canagliflozin 200 mg daily and requires additional glycemic control, management strategy is based on renal function.
    In Patients with eGFR ≥60 mL/min/1.73 m2
    • Canagliflozin dose may be increased to 300 mg daily.

    In Patients with eGFR <60 mL/min/1.73 m2
    • Consider adding another antihyperglycemic agent.
    SaxagliptinAll PIsATV/c, ATV/r, DRV/c, DRV/r↑ saxagliptin expectedLimit saxagliptin dose to 2.5 mg once daily.
    Dapagliflozin/SaxagliptinAll PIsATV/c, ATV/r, DRV/c, DRV/r↑ saxagliptin expectedDo not coadminister. Dapagliflozin is only available as a coformulated drug that contains 5 mg of saxagliptin. When coadministered with EVG/c, the dose of saxagliptin should not exceed 2.5 mg once daily; thus, this combination is not recommended.
    Herbal Products
    St. John’s WortATV/c, ATV/r, DRV/c, DRV/r↓ PI expectedContraindicated.
    Hormonal Therapies—Contraceptives
    Injectable Contraceptives
    Depot MPA
    ATV/c, ATV/r, DRV/c, DRV/r↔ expectedNo dose adjustment needed
    Oral Contraceptives
    (e.g., desogestrel, drospirenone, ethinyl estradiol, levonorgestrel, norgestimate, norethindrone)
    ATV/cDrosperinone AUC ↑ 130%
    Ethinyl estradiol AUC ↓ 22%
    Contraindicated with drospirenone-containing hormonal contraceptive due to potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    ↔ ethinyl estradiol AUC and Cmin ↓ 25%
    ↔ levonorgestrel
    No dose adjustment needed.
    ATV/rEthinyl estradiol AUC ↓ 19% and Cmin ↓ 37%
    Norgestimate AUC ↑ 85%
    Norethindrone AUC ↑ 51% and Cmin ↑ 67%
    Oral contraceptive should contain at least 35 mcg of ethinyl estradiol.c
    ↑ drospirenone expected

    ↔ estetrol
    Clinical monitoring is recommended due to the potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    DRV/cDrospirenone AUC ↑ 58%
    Ethinyl estradiol AUC ↓ 30%
    Clinical monitoring is recommended due to the potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    DRV/rEthinyl estradiol AUC ↓ 44% and Cmin ↓ 62%
    Norethindrone AUC ↓ 14% and Cmin ↓ 30%
    When Used for Contraception

    • Consider alternative ARV or contraceptive methods. If combined, consider using an oral contraceptive with at least 35 mcg of ethinyl estradiol.


    When Used for Other Clinical Indications (e.g., Acne, Menstrual Cycle Regulation)

    • Monitor for clinical effectiveness of hormonal therapy.

    Subdermal Implant Contraceptives
    (e.g., etonogestrel, levonorgestrel)
    ATV/c, ATV/r, DRV/c, DRV/r↑ etonogestrel, levonorgestrel expectedNo dose adjustment needed.
    Transdermal Contraceptives
    (e.g., ethinyl estradiol/norelgestromin, ethinyl estradiol/levonorgestrel)
    ATV/c, ATV/r, DRV/c, DRV/r↓ ethinyl estradiol possible with ritonavir

    ↑ ethinyl estradiol possible with cobicistat

    ↑ norelgestromin, levonorgestrel possible
    No dose adjustment needed.
    Vaginal Ring Contraceptives
    (e.g., etonogestrel/ethinyl estradiol, segesterone/ethinyl estradiol)
    ATV/rEthinyl estradiol AUC ↓ 26%

    Etonogestrel AUC ↑ 79%
    No dose adjustment needed.
    ATV/c, DRV/c, DRV/r↓ ethinyl estradiol possible with ritonavir

    ↑ ethinyl estradiol possible with cobicistat
    Emergency Contraceptives
    Levonorgestrel (oral)
    ATV/c, ATV/r, DRV/c, DRV/r↑ levonorgestrel expectedNo dose adjustment needed.
    Hormonal Therapies—Miscellaneous
    5-Alpha Reductase Inhibitors
    (e.g., dutasteride, finasteride)
    ATV/c, ATV/r, DRV/c, DRV/r↑ dutasteride possible

    ↑ finasteride possible
    Adjust dutasteride dose as needed based on clinical effects. No dose adjustment needed for finasteride.
    Hormonal Therapies—MiscellaneousAll PIs↔ goserelin, leuprolide acetate, and spironolactone expectedNo dose adjustment needed.
    EstradiolATV/c, DRV/c↓ or ↑ estradiol possibleAdjust estradiol dose as needed based on clinical effects.
    ATV/r, DRV/r↓ estradiol possible
    Goserelin, Leuprolide Acetate, SpironolactoneATV/c, ATV/r, DRV/c, DRV/r↔ goserelin, leuprolide acetate, and spironolactone expectedNo dose adjustment needed
    Menopausal Hormone Replacement Therapy
    (e.g., conjugated estrogens, drospirenone, estradiol, MPA, progesterone)
    ATV/c, ATV/r, DRV/c, DRV/r↓ or ↑ estrogen possible with estradiol or conjugated estrogen (equine and synthetic)Adjust estrogen dose as needed based on clinical effects.
    ATV/c, ATV/r, DRV/c, DRV/r↑ drospirenone possible

    ↑ MPA

    ↑ micronized progesterone

    See the Hormonal Therapies—Contraceptives section for other progestin-PI interactions.
    Adjust progestin/progesterone dose as needed based on clinical effects. Drospirenone is not contraindicated with ATV/c products because it is prescribed at a lower dose for menopausal HRT than products used for hormonal contraceptives.
    TestosteroneATV/c, ATV/r, DRV/c, DRV/r↑ testosterone possibleAdjust testosterone dose as needed based on clinical effects.
    Immunosuppressants
    Cyclosporine, Sirolimus, TacrolimusATV/c, ATV/r, DRV/c, DRV/r↑ immunosuppressant expectedInitiate with an adjusted dose of immunosuppressant to account for potential increased concentrations of the immunosuppressant and monitor for immunosuppressant-related adverse events. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with a specialist as necessary.
    EverolimusDRV/c, DRV/rDRV/c, DRV/rDo not coadminister.
    ATV/c, ATV/r↑ immunosuppressant expectedInitiate with an adjusted dose of immunosuppressant to account for potential increased concentrations of the immunosuppressant and monitor for immunosuppressant-related adverse events. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with a specialist as necessary.
    Lipid-Modifying
    AtorvastatinATV/r↑ atorvastatin possibleAdminister the lowest effective atorvastatin dose while monitoring for adverse events.
    ATV/cAtorvastatin AUC ↑ 9.2-fold and Cmax ↑ 18.9-foldDo not coadminister.
    DRV/cAtorvastatin AUC ↑ 3.9-fold and Cmax ↑ 4.2-foldAdminister the lowest effective atorvastatin dose while monitoring for adverse events. Do not exceed 20 mg atorvastatin daily.
    DRV/rDRV/r plus atorvastatin 10 mg similar to atorvastatin 40 mg administered aloneAdminister the lowest effective atorvastatin dose while monitoring for adverse events. Do not exceed 20 mg atorvastatin daily.
    FluvastatinATV/c, DRV/c↑ fluvastatin expectedAdminister the lowest effective fluvastatin dose while monitoring for adverse events.
    ATV/r, DRV/r↑ or ↓ fluvastatin possible
    LomitapideATV/c, ATV/r, DRV/c, DRV/r↑ lomitapide expectedContraindicated.
    LovastatinATV/c, ATV/r, DRV/c, DRV/rSignificant ↑ lovastatin expectedContraindicated.
    PitavastatinATV/c, ATV/r, DRV/c, DRV/rWith Unboosted ATV
    • ↑ pitavastatin AUC 31% and Cmax ↑ 60%
    • ↔ ATV

    With DRV/r
    • ↓ pitavastatin AUC 26%
    • ↔ DRV/r

    With LPV/r
    • ↓ pitavastatin AUC 20%
    • ↔ LPV
    No dose adjustment needed.
    PravastatinATV/c, DRV/cNo dataAdminister the lowest effective pravastatin dose while monitoring for adverse events.
    DRV/c, DRV/rWith DRV/r
    • Pravastatin AUC ↑ 81% following single dose of pravastatin
    • Pravastatin AUC ↑ 23% at steady state
    Administer the lowest effective pravastatin dose while monitoring for adverse events.
    PravastatinATV/c, ATV/rNo dataAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 10 mg daily.
    DRV/c, DRV/rWith DRV/r

    • Pravastatin AUC ↑ 81% following single dose of pravastatin

    • Pravastatin AUC ↑ 23% at steady state
    Administer the lowest effective pravastatin dose while monitoring for adverse events.
    RosuvastatinATV/rRosuvastatin AUC ↑ 3-fold and Cmax ↑ 7-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 10 mg daily.
    ATV/cRosuvastatin AUC ↑ 3.4-fold and Cmax ↑ 10.6-fold
    DRV/cRosuvastatin AUC ↑ 1.9-fold and Cmax ↑ 3.8-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 20 mg daily.
    DRV/rRosuvastatin AUC ↑ 48% and Cmax↑ 2.4-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events.
    SimvastatinATV/c, ATV/r, DRV/c, DRV/rSignificant ↑ simvastatin expectedContraindicated.
    Narcotics and Treatment for Opioid Dependence
    Buprenorphine
    Sublingual, buccal, or implant
    ATV/rBuprenorphine AUC ↑ 66%
    Norbuprenorphine (active metabolite) AUC ↑ 105%
    Monitor for sedation and other signs or symptoms of overmedication. Buprenorphine dose reduction may be necessary. It may be necessary to remove the implant and treat with a formulation that permits dose adjustments.
    DRV/r↔ buprenorphine
    Norbuprenorphine (active metabolite) AUC ↑ 46% and Cmin ↑ 71%
    No dose adjustment needed. Monitor for buprenorphine-related adverse events. When transferring buprenorphine from transmucosal delivery to implantation, monitor to ensure buprenorphine effect is adequate and not excessive
    ATV/c, DRV/c↑ buprenorphine possibleTitrate buprenorphine dose using the lowest initial dose. Dose adjustment of buprenorphine may be needed. It may be necessary to remove implant and treat with a formulation that permits dose adjustments. Monitor for buprenorphine-related adverse events.
    FentanylATV/c, ATV/r, DRV/c, DRV/r↑ fentanyl possibleMonitor for fentanyl-related adverse events, including potentially fatal respiratory depression
    LofexidineATV/c, ATV/r, DRV/c, DRV/r↑ lofexidine possibleMonitor for lofexidine-related adverse events, including symptoms of orthostasis and bradycardia.
    MethadoneATV/c, DRV/cNo dataTitrate methadone dose using the lowest feasible initial dose. Dose adjustment of methadone may be needed. Monitor for methadone-related adverse events.
    ATV/r, DRV/rATV/r and DRV/r ↓ R-methadoned AUC 16% to 18%
    LPV/r ↓ methadone AUC 26% to 53%
    Opioid withdrawal is unlikely, but may occur. Monitor for opioid withdrawal and increase methadone dose as clinically indicated.
    OxycodoneATV/c, ATV/r, DRV/c, DRV/rLPV/r ↑ oxycodone AUC 2.6-fold
    Other PIs: ↑ oxycodone expected
    Monitor for opioid-related adverse events, including potentially fatal respiratory depression. Oxycodone dose reduction may be necessary.
    TramadolATV/c, ATV/r, DRV/c, DRV/r↑ tramadol expected
    ↓ M1 (active metabolite) possible
    Tramadol dose adjustments may be necessary. Monitor for clinical response and tramadol-related adverse events.
    PDE5 Inhibitors
    AvanafilATV/c, ATV/r, DRV/c, DRV/rRTV 600 mg twice daily (for 5 days) ↑ avanafil AUC 13-fold and ↑ Cmax 2.4-foldDo not coadminister.
    SildenafilATV/c, ATV/r, DRV/c, DRV/rDRV/r plus sildenafil 25 mg similar to sildenafil 100 mg alone

    RTV 500 mg twice daily ↑ sildenafil AUC 1,000%
    For Treatment of Erectile Dysfunction
    • Start with sildenafil 25 mg every 48 hours and monitor for adverse events of sildenafil.

    Contraindicated for treatment of PAH.
    TadalafilATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily ↑ tadalafil AUC 124%RTV 200 mg twice daily ↑ tadalafil AUC 124%
    • Start with tadalafil 5 mg and do not exceed a single dose of tadalafil 10 mg every 72 hours. Monitor for adverse events of tadalafil.

    For Treatment of PAH
    In Patients on a PI >7 Days
    • Start with tadalafil 20 mg once daily and increase to tadalafil 40 mg once daily based on tolerability.

    In Patients on Tadalafil who Require a PI
    • Stop tadalafil ≥24 hours before PI initiation. Seven days after PI initiation, restart tadalafil at 20 mg once daily and increase to tadalafil 40 mg once daily based on tolerability.

    In Patients Switching between COBI and RTV
    • Maintain tadalafil dose.

    For Treatment of Benign Prostatic Hyperplasia
    • Maximum recommended daily dose is tadalafil 2.5 mg per day.
    VardenafilATV/c, ATV/r, DRV/c, DRV/rRTV 600 mg twice daily ↑ vardenafil AUC 49-foldStart with vardenafil 2.5 mg every 72 hours and monitor for adverse events of vardenafil.
    Sedative/Hypnotics
    Benzodiazepines
    Alprazolam, Clonazepam, DiazepamATV/c, ATV/r, DRV/c, DRV/r↑ benzodiazepine possible
    RTV 200 mg twice daily (for 2 days) ↑ alprazolam half-life 222% and ↑ AUC 248%
    Consider alternative benzodiazepines, such as lorazepam, oxazepam, or temazepam.
    Lorazepam, Oxazepam, TemazepamATV/c, ATV/r, DRV/c, DRV/rNo dataThese benzodiazepines are metabolized via non-CYP450 pathways and therefore have less interaction potential than other benzodiazepines.
    MidazolamATV/c, ATV/r, DRV/c, DRV/r↑ midazolam expectedOral midazolam is contraindicated with PIs.
    Parenteral midazolam can be used with caution when given in a monitored situation with appropriate medical management available in case of respiratory sedation and/or prolonged sedation. Consider dose reduction, especially if more than a single dose of midazolam is administered.
    TriazolamATV/c, ATV/r, DRV/c, DRV/r↑ triazolam expected
    RTV 200 mg twice daily ↑ triazolam half-life 1,200% and ↑ AUC 2,000%
    Contraindicated.
    Orexin Receptor Antagonist
    Daridorexant, Lemborexant, SuvorexantATV/c, ATV/r, DRV/c, DRV/r↑ daridorexant, lemborexant, suvorexant expectedDo not coadminister.
    Other Sedatives
    EszopicloneATV/c, ATV/r, DRV/c, DRV/r↑ eszopiclone possibleStart with lowest dose and increase to a maximum of 2 mg daily; monitor for eszopiclone-related adverse events.
    ZolpidemATV/c, ATV/r, DRV/c, DRV/r↑ zolpidem possibleInitiate zolpidem at a low dose and monitor for zolpidem-related adverse events. Dose reduction may be necessary.
    Miscellaneous
    CalcifediolATV/c, ATV/r, DRV/c, DRV/r↑ calcifediol possibleDose adjustment of calcifediol may be required, and serum 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations should be closely monitored.
    CisaprideATV/c, ATV/r, DRV/c, DRV/r↑ cisapride expectedContraindicated.
    ColchicineATV/c, ATV/r, DRV/c, DRV/rRTV 100 mg twice daily ↑ colchicine AUC 296% and Cmax ↑ 184%

    Significant ↑ colchicine expected with all PIs, with or without COBI or RTV
    For Treatment of Gout Flares
    • Administer a single dose of colchicine 0.6 mg, followed by colchicine 0.3 mg 1 hour later. Do not repeat dose for at least 3 days

    For Prophylaxis of Gout Flares
    • If original dose was colchicine 0.6 mg twice daily, decrease to colchicine 0.3 mg once daily. If dose was 0.6 mg once daily, decrease to 0.3 mg every other day.

    For Treatment of Familial Mediterranean Fever
    • Do not exceed colchicine 0.6 mg once daily or colchicine 0.3 mg twice daily.

    Contraindicated in patients with hepatic (Child-Pugh Score A, B or C) or renal impairment (CrCl <60 mL/min).
    DronabinolATV/c, ATV/r, DRV/c, DRV/r↑ dronabinol possibleMonitor for dronabinol-related adverse events.
    EluxadolineATV/c, ATV/r, DRV/c, DRV/r↑ eluxadoline expectedAdminister eluxadoline at a dose of 75 mg twice daily and monitor for eluxadoline-related adverse events.
    Ergot DerivativesATV/c, ATV/r, DRV/c, DRV/r↑ dihydroergotamine, ergotamine, and methylergonovine expectedContraindicated.
    FlibanserinATV/c, ATV/r, DRV/c, DRV/r↑ flibanserin expectedContraindicated.
    a DHA is an active metabolite of artemether and artesunate.

    bThe following products contain no more than 30 mcg of ethinyl estradiol combined with norethindrone or norgestimate: Lo Minastrin Fe; Lo Loestrin Fe; Loestrin 1/20, 1.5/30; Loestrin Fe 1/20, 1.5/30; Loestrin 24 Fe; Minastrin 24 Fe; Ortho Tri-Cyclen Lo. Generic formulations also may be available.


    cThe following products contain at least 35 mcg of ethinyl estradiol combined with norethindrone or norgestimate: Brevicon; Femcon Fe; Modicon; Norinyl 1/35; Ortho-Cyclen; Ortho-‍Novum 1/35, 7/7/7; Ortho Tri-Cyclen; Ovcon 35; Tri-Norinyl. Generic formulations also may be available.


    dR-methadone is the active form of methadone.

    Key to Symbols

    ↑ = increase
    ↓ = decrease
    ↔ = less than 20% change in AUC

    Key: 17-BMP = beclomethasone 17-monopropionate; ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; CCB = calcium channel blocker; CNS = central nervous system; COBI = cobicistat; CrCl = creatinine clearance; CMV = cytomegalovirus; CV = cardiovascular; CYP = cytochrome P; DHA = dihydroartemisinin; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DVT = deep vein thrombosis; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; EVG/c = elvitegravir/cobicistat; GI = gastrointestinal; H2RA = H2 receptor antagonist; HCV = hepatitis C virus; HRT = hormone replacement therapy; INR = international normalized ratio; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MPA = medroxyprogesterone acetate; OATP = organic anion-transporting polypeptide; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase type 5; PE = pulmonary embolism; PI = protease inhibitor; PI/c = protease inhibitor/cobicistat; PI/r = protease inhibitor/ritonavir; PK = pharmacokinetic; PPI = proton pump inhibitor; PTH = parathyroid hormone; QTc = QT corrected for heart rate; RTV = ritonavir; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; TDF = tenofovir disoproxil fumarate; VPA = valproic acid

    Table 24a. Drug Interactions Between Protease Inhibitors and Other Drugs

    This table provides information on the known or predicted interactions between protease inhibitors (PIs) and non-antiretroviral (ARV) drugs. When information is available, interactions for boosted atazanavir (ATV) (with either ritonavir [RTV] or cobicistat [COBI]) and unboosted ATV are listed separately. The term “all PIs” refers to both unboosted ATV and ATV, darunavir (DRV), and lopinavir (LPV) boosted with either RTV or COBI. This table does not include interactions for fosamprenavir (FPV), nelfinavir (NFV), or tipranavir (TPV). For information regarding interactions between PIs and other ARV drugs, including dosing recommendations, refer to Tables 24c25a, and 25b.

    Recommendations for managing a particular drug interaction may differ depending on whether a new ARV drug is being initiated in a patient on a stable concomitant medication or whether a new concomitant medication is being initiated in a patient on a stable ARV regimen. The magnitude and significance of drug interactions are difficult to predict when several drugs with competing metabolic pathways are prescribed concomitantly. In cases where an interacting drug needs to be replaced with an alternative, providers should exercise their clinical judgement to select the most appropriate alternative medication to use.

    Note: FPV, NFV, and TPV are no longer commonly used in clinical practice and are not included in this table. Please refer to the U.S. Food and Drug Administration product labels for information regarding drug interactions between these PIs and concomitant medications.

    Concomitant Drug
    PI
    Effect on PI and/or Concomitant Drug Concentrations
    Dosing Recommendations and Clinical Comments
    Acid Reducers
    AntacidsATV (unboosted), ATV/c, ATV/rWhen Given Simultaneously
    • ↓ ATV expected
    Administer ATV at least 2 hours before or 2 hours after antacids or buffered medications.
    H2 Receptor AntagonistsATV/c, ATV/r↓ ATV expectedH2RA dose should not exceed a dose equivalent to famotidine 40 mg twice daily in ART-naive patients or famotidine 20 mg twice daily in ART-experienced patients.

    Give ATV 300 mg (plus COBI 150 mg or RTV 100 mg) with food simultaneously with and/or ≥10 hours after the dose of H2RA.

    If using TDF and H2RA in ART-experienced patients, administer ATV 400 mg plus RTV 100 mg with food simultaneously with and/or ≥10 hours after the dose of H2RA.

    Do not coadminister ATV/c with TDF and H2RA in ART-experienced patients.
    DRV/c, DRV/r, LPV/rWith Ranitidine
    • ↔ DRV/r
    No dose adjustment needed.
    Proton Pump InhibitorsATV/c, ATV/rWith Omeprazole 40 mg
    • ATV AUC ↓ 76%

    When Omeprazole 20 mg Is Given 12 Hours before ATV/c or ATV/r
    • ATV AUC ↓ 42%
    PPI dose should not exceed a dose equivalent to omeprazole 20 mg daily in PI-naive patients.

    PPIs should be administered at least 12 hours before ATV/c or ATV/r.
    Do not coadminister in PI-experienced patients.
    DRV/c, LPV/r↔ PI expectedNo dose adjustment needed.
    DRV/r↔ DRV/r
    Omeprazole AUC ↓ 42%
    Consider alternative ARV or acid reducer. If coadministered, monitor for omeprazole efficacy. If the patient does not experience symptomatic relief, increase the dose to no more than omeprazole 40 mg daily.
    Alpha-Adrenergic Antagonists for Benign Prostatic Hyperplasia
    AlfuzosinATV/c, ATV/r, DRV/c, DRV/r↑ alfuzosin expectedContraindicated.
    DoxazosinATV/c, ATV/r, DRV/c, DRV/r↑ doxazosin possibleInitiate doxazosin at lowest dose and titrate. Monitor blood pressure. Dose reduction may be necessary.
    TamsulosinATV/c, ATV/r, DRV/c, DRV/r↑ tamsulosin expectedDo not coadminister unless benefits outweigh risks. If coadministered, monitor blood pressure.
    TerazosinATV/c, ATV/r, DRV/c, DRV/r↔ or ↑ terazosin possibleInitiate terazosin at lowest dose and titrate. Monitor blood pressure. Dose reduction may be necessary.
    SilodosinATV/c, ATV/r, DRV/c, DRV/r↑ silodosin expectedContraindicated.
    Antibacterials—Antimycobacterials
    BedaquilineAll PIsWith LPV/r
    • Bedaquiline AUC ↑ 1.9-fold

    With Other PI/r, ATV/c, or DRV/c
    • ↑ bedaquiline possible
    Do not coadminister unless benefits outweigh risks. If coadministered, consider therapeutic drug monitoring and monitor for bedaquiline-related adverse effects, including hepatotoxicity and QTc prolongation.
    RifabutinATV/rCompared With Rifabutin (300 mg Once Daily) Alone, Rifabutin (150 mg Once Daily) Plus ATV/r
    • Rifabutin AUC ↑ 110% and metabolite AUC ↑ 2,101%
    Recommended dose is rifabutin 150 mg once daily.

    Monitor for antimycobacterial activity and consider therapeutic drug monitoring. Monitor for rifabutin-related adverse events, including neutropenia and uveitis.

    PK data in this table are results from healthy volunteer studies. Lower rifabutin exposure has been reported in patients with HIV than in healthy study participants.
    DRV/rCompared With Rifabutin (300 mg Once Daily) Alone, Rifabutin (150 mg Every Other Day) Plus DRV/r
    • ↔ rifabutin AUC and metabolite AUC ↑ 881%
    ATV/c, DRV/c↑ rifabutin expected
    ↓ COBI expected
    Do not coadminister.
    RifampinATV/c, ATV/r, DRV/c, DRV/r↓ PI concentration by >75%Contraindicated. Increasing the dose of RTV does not overcome this interaction and may increase hepatotoxicity. Increasing the COBI dose is not recommended. Consider rifabutin if a rifamycin is indicated.
    RifapentineATV/c, ATV/r, DRV/c, DRV/r Daily and Weekly Dosing
    ↓ PI expected
    Do not coadminister.
    Antibacterials—Macrolides
    AzithromycinATV (unboosted), ATV/c, ATV/r↑ azithromycin possibleNo dose adjustment needed.
    DRV/c, DRV/r↔ azithromycin expectedNo dose adjustment needed.
    ClarithromycinATV/c, ATV/r, DRV/c↑ clarithromycin expected
    ↑ ATV/r and PI/c expected
    Consider alternative ARV or azithromycin.
    DRV/r, LPV/rDRV/r ↑ clarithromycin AUC 57%
    LPV/r ↑ clarithromycin expected
    RTV 500 mg twice daily ↑ clarithromycin 77%
    Consider alternative ARV or azithromycin.

    If use of clarithromycin is necessary in a patient with impaired renal function, reduce clarithromycin dose by 50% in patients with CrCl 30 to 60 mL/min. In patients with CrCl <30 mL/min, reduce clarithromycin dose by 75%.
    Monitor for clarithromycin-related adverse events, including QTc prolongation.
    ErythromycinATV/c, ATV/r, DRV/c, DRV/r↑ erythromycin expected
    ↑ PIs expected
    Consider alternative ARV or use azithromycin.
    Anticoagulants
    ApixabanATV/c, ATV/r, DRV/c, DRV/r↑ apixaban expectedDo not coadminister in patients who require apixaban 2.5 mg twice daily.
    In Patients Requiring Apixaban 5 mg or 10 mg Twice Daily
    • Reduce apixaban dose by 50%.

    DabigatranATV/c, ATV/rWith COBI 150 mg Alone
    • Dabigatran AUC ↑ 110% to 127%

    With ATV/r
    • ↑ dabigatran expected
    Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation in Adult Patients

    • CrCl >30 mL/min: no dose adjustment needed

    • CrCl ≤30 mL/min: do not coadminister.


    Treatment and Reduction in the Risk of Recurrence of DVT and PE or Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients

    • CrCl ≥50 mL/min: no dose adjustment needed

    • CrCl <50 mL/min: do not coadminister.
    DRV/c, DRV/rWith DRV/c
    • Single dose DRV/c: dabigatran AUC ↑ 164%
    • After 14 days of DRV/c: dabigatran AUC ↑ 88%

    With DRV/r
    • Single dose DRV/r: dabigatran AUC ↑ 72%
    • After 14 days of daily DRV/r: dabigatran AUC ↑ 18%
    EdoxabanATV/r, ATV/c↑ edoxaban expectedStroke Prevention in Nonvalvular Atrial Fibrillation Indication
    • No dose adjustment needed.

    Deep Venous Thrombosis and Pulmonary Embolism Indication
    • Administer edoxaban 30 mg once daily.

    DRV/r↑ edoxaban expectedStroke Prevention in Nonvalvular Atrial Fibrillation Indication
    • No dose adjustment needed.

    Deep Venous Thrombosis and Pulmonary Embolism Indication
    • No dose adjustment needed

    RivaroxabanATV/c, ATV/r, DRV/c, DRV/r↑ rivaroxaban possibleDo not coadminister.
    WarfarinATV/c, DRV/c↑ warfarin possibleMonitor INR closely when stopping or starting PI/c or PI/r and adjust warfarin dose accordingly.

    If switching between RTV and COBI, the effect of COBI on warfarin is not expected to be equivalent to RTV’s effect on warfarin.
    ATV/r, DRV/r↓ warfarin possible
    Antidepressants, Anxiolytics, and Antipsychotics
    Also see the Sedative/Hypnotics section below
    Antidepressants, Anxiolytics
    BupropionATV/r, DRV/r↓ bupropion possibleTitrate bupropion dose based on clinical response.
    ATV/c, DRV/c↔ bupropion expectedNo dose adjustment needed.
    BuspironeATV/c, ATV/r, DRV/c, DRV/r↑ buspirone expectedAdminister lowest dose of buspirone with caution and titrate buspirone dose based on clinical response. Dose reduction may be necessary. Monitor for buspirone-related adverse events.
    DesvenlafaxineATV/c, ATV/r, DRV/c, DRV/r↑ desvenlafaxine expectedNo dose adjustment needed.
    DuloxetineATV/c, ATV/r, DRV/c, DRV/r↑ duloxetine expectedNo dose adjustment needed.
    MirtazapineATV/c, ATV/r, DRV/c, DRV/r↑ mirtazapine expectedMonitor for mirtazapine-related adverse events. Mirtazapine dose reduction may be necessary.
    NefazodoneATV/c, ATV/r, DRV/c, DRV/r↑ nefazodone expected
    ↑ PI possible
    Monitor for nefazodone-related adverse events and PI tolerability.
    Selective Serotonin Reuptake Inhibitors
    (e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, vortioxetine)
    DRV/rParoxetine AUC ↓ 39%
    Sertraline AUC ↓ 49%
    Titrate SSRI dose based on clinical response.
    ATV/c, ATV/r, DRV/c↑ or ↓ SSRI possibleTitrate SSRI dose using the lowest available initial or maintenance dose.
    TrazodoneATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily (for 2 days)
    • Trazodone ↑ AUC 240%
    Administer lowest dose of trazodone and monitor for CNS and CV adverse events.
    Tricyclic Antidepressants
    Amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, trimipramine
    ATV/c, ATV/r, DRV/c, DRV/r↑ TCA expectedAdminister lowest possible TCA dose and titrate based on clinical assessment and/or drug concentrations. Monitor for TCA-related adverse events.
    VenlafaxineATV/c, ATV/r, DRV/c, DRV/r↑ venlafaxine and O-desmethylvenlafaxine expectedMonitor for venlafaxine-related adverse events. Consider venlafaxine dose reduction.
    Antipsychotics
    AripiprazoleATV/c, ATV/r, DRV/c, DRV/r↑ aripiprazole expectedAdminister 25% of the usual aripiprazole dose. Titrate dose based on clinical monitoring for effectiveness/adverse events. Refer to aripiprazole label for doses to use in patients who have major depressive disorder or who are known to be CYP2D6-poor metabolizers.
    BrexpiprazoleATV/c, ATV/r, DRV/c, DRV/r↑ brexpiprazole expectedAdminister 25% of the usual brexpiprazole dose. Titrate the dose based on clinical monitoring for efficacy/adverse events. Refer to brexpiprazole label for doses to use in patients who have major depressive disorder or who are known to be CYP2D6 poor metabolizers.
    CariprazineATV/c, ATV/r, DRV/c, DRV/r↑ cariprazine expectedStarting Cariprazine in a Patient Who Is Already Receiving a PI
    • Administer cariprazine 1.5 mg on Day 1 and Day 3, with no dose given on Day 2. From Day 4 onward, administer cariprazine 1.5 mg daily. Dose can be increased to a maximum of cariprazine 3 mg daily. If the PI is withdrawn, cariprazine dose may need to be increased.

    Starting a PI in a Patient Who Is Already Receiving Cariprazine
    • For patients receiving cariprazine 3 mg or cariprazine 6 mg daily, reduce the dose by half. For patients taking cariprazine 4.5 mg daily, the dose should be reduced to cariprazine 1.5 mg or cariprazine 3 mg daily. For patients taking cariprazine 1.5 mg daily, change to cariprazine 1.5 mg every other day. If PI is withdrawn, the cariprazine dose may need to be increased.
    IloperidoneATV/c, ATV/r, DRV/c, DRV/r↑ iloperidone expectedDecrease iloperidone dose by 50%.
    LumateperoneATV/c, ATV/r, DRV/c, DRV/r↑ lumateperone expectedDo not coadminister.
    LurasidoneATV/c, ATV/r, DRV/c, DRV/r↑ lurasidone expectedContraindicated.
    Olanzapine, Olanzapine/SamidorphanATV/c, DRV/c↔ olanzapine expected

    ↑ samidorphan possible
    No dose adjustment needed.
    ATV/r, DRV/r↓ olanzapine possibleMonitor for therapeutic effectiveness of olanzapine.
    Other Antipsychotics
    CYP3A4 and/or CYP2D6 substrates (e.g., clozapine, perphenazine, risperidone, thioridazine)
    ATV/c, ATV/r, DRV/c, DRV/r↑ antipsychotic possibleTitrate the antipsychotic dose using the lowest initial dose or adjust the maintenance dose accordingly. Monitor for adverse events, including QTc prolongation.
    PimavanserinATV/c, ATV/r, DRV/c, DRV/r↑ pimavanserin expectedReduce pimavanserin dose to 10 mg once daily.
    PimozideATV/c, ATV/r, DRV/c, DRV/r↑ pimozide expectedContraindicated.
    QuetiapineATV/c, ATV/r, DRV/c, DRV/r↑ quetiapine expectedStarting Quetiapine in a Patient Receiving a PI
  • Initiate quetiapine at the lowest dose and titrate up as needed. Monitor for quetiapine effectiveness and adverse events, including QTc prolongation.

  • Starting a PI in a Patient Receiving a Stable Dose of Quetiapine
    • Consider alternative ARV. If coadministered, reduce quetiapine dose to 1/6 of the current dose. Closely monitor for quetiapine effectiveness and adverse events, including QTc prolongation.
    ZiprasidoneATV/c, ATV/r, DRV/c, DRV/r↑ ziprasidone expectedMonitor for ziprasidone-related adverse events, including QTc prolongation.
    Antimigraine
    Ergot DerivativesATV/c, ATV/r, DRV/c, DRV/r↑ dihydroergotamine, ergotamine, and methylergonovine expectedContraindicated.
    Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
    AtogepantATV/c, ATV/r, DRV/c, DRV/r↑ atogepant expectedChronic migraine: Do not coadminister.

    Episodic migraine: Administer atogepant at a dose of 10 mg once daily.
    RimegepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedDo not coadminister.
    UbrogepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedContraindicated.
    ZavegepantATV/c, ATV/r, DRV/c, DRV/r↑ rimegepant expectedDo not coadminister.
    DRV/r↔ zavegepant expectedNo dose adjustment needed
    Serotonin 5-HT1B, 1D Receptor Agonists
    AlmotriptanATV/c, ATV/r, DRV/c, DRV/r↑ almotriptan expected No dose adjustment needed
    EletriptanATV/c, ATV/r, DRV/c, DRV/r↑ eletriptan expectedContraindicated.
    Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan ZolmitriptanATV/c, ATV/r, DRV/c, DRV/r↔ triptan expectedNo dose adjustment needed
    Antifungals
    FluconazoleATV/c, ATV/r, DRV/c, DRV/r↔ PI expected
    ↔ fluconazole expected
    No dose adjustment needed.
    IsavuconazoleATV/c, DRV/c↑ isavuconazole expected

    ↓ PI possible
    Contraindicated.
    ATV/r, DRV/r↑ isavuconazole expected

    ↓ PI possible
    If coadministered, monitor isavuconazole concentrations and monitor for isavuconazole-related adverse events. Monitor for PI tolerability.
    IbrexafungerpATV/c, ATV/r, DRV/c, DRV/r↑ ibrexafungerp expectedReduce ibrexafungerp dose to 150 mg twice daily.
    ItraconazoleATV/c, ATV/r, DRV/c, DRV/r↑ itraconazole expected
    ↑ PI expected
    Itraconazole doses >200 mg/day are not recommended unless dosing is guided by itraconazole concentrations.
    PosaconazoleATV/rATV AUC ↑ 146%
    ↑ posaconazole possible
    If coadministered, monitor posaconazole concentrations and monitor for posaconazole-related or PI-related adverse events.
    ATV/c, DRV/c, DRV/r↑ PI expected
    ↑ posaconazole possible
    VoriconazoleATV/c, DRV/cNo data
    ATV/r, DRV/rRTV 100 mg twice daily ↓ voriconazole AUC 39%Do not coadminister voriconazole and RTV or COBI unless benefits outweigh risks. If coadministered, monitor voriconazole concentration and adjust dose accordingly.
    Antimalarials
    Artemether/LumefantrineATV/c, DRV/c↑ lumefantrine expected

    ↑ artemether possible
    Clinical significance is unknown. If coadministered, monitor closely for antimalarial efficacy and lumefantrine-related adverse events, including QTc prolongation.
    DRV/rArtemether AUC ↓ 16%
    DHAa AUC ↓ 18%
    Lumefantrine AUC ↑ 175%
    ↔ DRV
    ArtesunateATV/c ↑ DHAa possibleMonitor for artesunate-related adverse effects.
    DRV/c↓ DHAa possibleNo dose adjustment needed
    ATV/r, DRV/r↓ DHAa possibleMonitor for artesunate-related adverse effects.
    Atovaquone/ProguanilATV/r, DRV/rWith ATV/r
    • Atovaquone AUC ↓ 46%
    • Proguanil AUC ↓ 41%

    With LPV/r
    • Atovaquone AUC ↓ 74%
    • Proguanil AUC ↓ 38%
    Clinical significance is unknown. Consider alternative ARV or malaria prophylaxis.
    ATV/c, DRV/c↔ atovaquone/proguanil expectedNo dose adjustment needed
    MefloquineAll PIsWith RTV 200 mg Twice Daily
    • RTV AUC ↓ 31% and Cmin ↓ 43%
    • ↔ mefloquine

    With ATV (Unboosted), PI/c, or PI/r
    • No data
    • ↑ mefloquine possible
    Clinical significance is unknown. Consider alternative ARV or antimalarial drug. If coadministered, monitor for mefloquine-related adverse events, including psychiatric symptoms and QTc prolongation. Monitor virologic response.
    Antiplatelets
    ClopidogrelATV/c, ATV/r, DRV/c, DRV/rClopidogrel active metabolite AUC ↓ 69% in people with HIV compared to healthy volunteers without HIV. Impaired platelet inhibition observed in people with HIV.Do not coadminister.
    PrasugrelATV/c, ATV/r, DRV/c, DRV/rPrasugrel active metabolite AUC ↓ 52% in people with HIV compared to healthy volunteers without HIV. Adequate platelet inhibition observed in people with HIV.No dose adjustment needed.
    TicagrelorATV/c, ATV/r, DRV/c, DRV/r↑ ticagrelor expectedDo not coadminister.
    VorapaxarATV/c, ATV/r, DRV/c, DRV/r↑ vorapaxar expectedDo not coadminister.
    Antipneumocystis and Antitoxoplasmosis Drug
    Atovaquone
    Oral suspension
    ATV/r↔ atovaquoneNo dose adjustment needed.
    ATV/c, DRV/c, DRV/r↔ atovaquone expectedNo dose adjustment needed.
    Antiseizure
    CarbamazepineATV/r↑ carbamazepine possible
    May ↓ PI concentrations substantially
    Consider alternative ARV or anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assess virologic response. Carbamazepine dose reduction may be necessary.
    Do not coadminister with LPV/r once daily.
    DRV/rCarbamazepine AUC ↑ 45%
    ↔ DRV
    Monitor anticonvulsant concentration and adjust dose accordingly.
    ATV/c, DRV/c↑ carbamazepine possible
    ↓ COBI expected
    ↓ PI expected
    Contraindicated.
    EslicarbazepineATV/c, ATV/r, DRV/c, DRV/r↓ PI possibleConsider alternative ARV or anticonvulsant. If coadministration is necessary, monitor for virologic response. Consider monitoring anticonvulsant and PI concentrations.
    EthosuximideATV/c, ATV/r, DRV/c, DRV/r↑ ethosuximide possibleMonitor for ethosuximide-related adverse events.
    LamotrigineATV/rLamotrigine AUC ↓ 32%A dose increase of lamotrigine may be needed; monitor lamotrigine concentration or consider alternative ARV or anticonvulsant.
    DRV/r↓ lamotrigine possible
    ATV/cNo dataMonitor anticonvulsant concentration and adjust dose accordingly.
    DRV/c↔ lamotrigine expectedNo dose adjustment needed.
    OxcarbazepineATV/c, ATV/r, DRV/c, DRV/r↓ PI possibleConsider alternative ARV or anticonvulsant. If coadministration necessary, monitor for virologic response. Consider monitoring anticonvulsant and PI concentrations.
    PhenobarbitalATV/r, DRV/r↓ phenobarbital possible
    ↓ PI possible
    Consider alternative anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assessing virologic response.
    ATV/c, DRV/c↓ COBI expected

    ↓ PI expected
    Contraindicated.
    PhenytoinATV/r, DRV/r↓ phenytoin possible

    ↓ PI possible
    Consider alternative anticonvulsant. If coadministration is necessary, consider monitoring concentrations of both drugs and assessing virologic response.
    ATV/c, DRV/c↓ COBI expected

    ↓ PI expected
    Contraindicated.
    PrimidoneATV/c, ATV/r, DRV/c, DRV/r↓ PI expectedDo not coadminister.
    Valproic AcidATV/c, ATV/r, DRV/c, DRV/r↓ or ↔ VPA possible
    LPV AUC ↑ 38%
    No data for other PIs
    Monitor VPA concentrations and monitor for PI tolerability.
    Antivirals—Hepatitis C
    Elbasvir/GrazoprevirATV/rElbasvir AUC ↑ 4.8-fold
    Grazoprevir AUC ↑ 10.6-fold
    Elbasvir ↔ ATV
    Grazoprevir ↑ ATV AUC 43%
    Contraindicated.
    May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1/3 inhibition.
    DRV/rElbasvir AUC ↑ 66%
    Grazoprevir AUC ↑ 7.5-fold
    ↔ DRV
    ATV/c, DRV/c↑ grazoprevir expected
    Glecaprevir/PibrentasvirATV/c, ATV/rWith (ATV 300 mg plus RTV 100 mg) Once Daily
    • Glecaprevir AUC ↑ 6.5-fold
    • Pibrentasvir AUC ↑ 64%
    Contraindicated.
    DRV/c, DRV/rWith (DRV 800 mg plus RTV 100 mg) Once Daily
    • Glecaprevir AUC ↑ 5-fold
    • ↔ pibrentasvir
    Do not coadminister..
    Ledipasvir/SofosbuvirATV/rATV AUC ↑ 33%
    Ledipasvir AUC ↑ 113%
    ↔ sofosbuvir
    No dose adjustment needed.
    Coadministration of ledipasvir/sofosbuvir with TDF and a PI/r results in increased exposure to TDF. The safety of the increased TDF exposure has not been established. Consider alternative HCV or ARV drugs to avoid increased risk of TDF toxicities. If coadministration is necessary, monitor for TDF-related adverse events.
    ATV/c, DRV/c, DRV/rATV (unboosted), ATV/c, DRV/c, DRV/r, LPV/r
    Sofosbuvir/VelpatasvirATV/r↔ ATV/r

    ↔ sofosbuvir

    Velpatasvir AUC ↑ 2.4-fold
    No dose adjustment needed.
    DRV/r↔ DRV/r
    Sofosbuvir AUC ↓ 28%
    ↔ velpatasvir
    No dose adjustment needed.
    ATV/c, DRV/c↔ sofosbuvir and velpatasvir expectedNo dose adjustment needed.
    Sofosbuvir/Velpatasvir/VoxilaprevirATV/c, ATV/rWith ATV/r
    • Voxilaprevir AUC ↑ 4.3-fold
    • Velpatasvir AUC ↑ 93%
    • Sofosbuvir AUC ↑ 40%
    Do not coadminister.
    DRV/c, DRV/rWith DRV/r
    • Voxilaprevir AUC ↑ 2.4-fold
    • ↔ DRV/r, velpatasvir, and sofosbuvir
    No dose adjustment needed.
    Antivirals—Miscellaneous (e.g., for CMV, Mpox)
    BrincidofovirATV/c, ATV/r, DRV/c, DRV/r↑ brincidofovir possibleGive PI dose at least 3 hours after administering brincidofovir and monitor for brincidofovir-related adverse events (i.e., elevations in ALT/AST and bilirubin and GI adverse events).
    CidofovirATV/c, ATV/r, DRV/c, DRV/r↔ cidofovirNo dose adjustment needed.
    TecovirimatATV/c, ATV/r, DRV/c, DRV/r↔ tecovirimatNo dose adjustment needed.
    Antivirals—SARS-CoV-2
    MolnupiravirATV/c, ATV/r, DRV/c, DRV/r↔ molnupiravirNo dose adjustment needed
    RemdesivirATV/c, ATV/r, DRV/c, DRV/r↔ remdesivirNo dose adjustment needed
    Ritonavir-Boosted NirmatrelvirATV/c, ATV/r, DRV/c, DRV/r↑ PI expected

    ↑ ritonavir-boosted nirmatrelvir expected
    No dose adjustment needed. Monitor for increased ritonavir-boosted nirmatrelvir and PI-related adverse events.
    Beta-Agonists, Long-Acting Inhaled
    Arformoterol, FormoterolATV/c, ATV/r↑ arformoterol possibleNo dose adjustment needed.
    DRV/c, DRV/r, LPV/r↔ arformoterol expectedNo dose adjustment needed.
    IndacaterolATV/c, ATV/r, DRV/c, DRV/rWith RTV 300 mg Twice Daily
    • Indacaterol AUC ↑ 1.7-fold
    No dose adjustment needed in patients receiving indacaterol 75 mcg daily.
    OlodaterolATV/c, ATV/r, DRV/c, DRV/r↑ olodaterol expectedNo dose adjustment needed.
    SalmeterolATV/c, ATV/r, DRV/c, DRV/r↑ salmeterol possibleDo not coadminister, due to potential increased risk of salmeterol-related CV events.
    Cardiac Medications
    Antiarrhythmics
    AmiodaroneATV/r↑ amiodarone possible
    ↑ PI possible
    Contraindicated.
    ATV/c, DRV/c, DRV/r↑ amiodarone possible
    ↑ PI possible
    Do not coadminister unless the benefits outweigh the risks. If coadministered, monitor for amiodarone-related adverse events and consider monitoring ECG and amiodarone drug concentration.
    DigoxinATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily ↑ digoxin AUC 29% and ↑ half-life 43%

    DRV/r ↑ digoxin AUC 36%

    COBI ↑ digoxin Cmax 41% and ↔ AUC
    RTV 200 mg twice daily ↑ digoxin AUC 29% and ↑ half-life 43%

    DRV/r ↑ digoxin AUC 36%

    COBI ↑ digoxin Cmax 41% and ↔ AUC
    DisopyramideATV/c, ATV/r, DRV/c, DRV/r↑ disopyramide possibleDo not coadminister.
    DofetilideATV/c, ATV/r, DRV/c, DRV/r↑ dofetilide possibleDo not coadminister.
    DronedaroneATV/c, ATV/r, DRV/c, DRV/r↑ dronedarone possibleContraindicated.
    FlecainideATV/c, ATV/r, DRV/c, DRV/r↑ flecainide possibleConsider alternative ARV or antiarrhythmic. If coadministered, monitor flecainide concentrations and for antiarrhythmic-related adverse events.
    LidocaineATV/c, ATV/r, DRV/c, DRV/r↑ lidocaine possibleConsider alternative ARV or antiarrhythmic. If coadministered, monitor lidocaine concentrations and for antiarrhythmic-related adverse events.
    MexiletineATV/c, ATV/r, DRV/c, DRV/r↑ mexiletine possible Consider alternative ARV or antiarrhythmic. If coadministered, monitor mexiletine concentrations and for antiarrhythmic-related adverse events.
    PropafenoneATV/c, ATV/r, DRV/c, DRV/r↑ propafenone possibleDo not coadminister.
    QuinidineATV/r↑ quinidine expectedContraindicated.
    ATV/c, DRV/c, DRV/r↑ quinidine possibleDo not coadminister.
    SotalolATV/c, ATV/r, DRV/c, DRV/r↔ sotalol expectedNo dose adjustment needed
    Beta-Blockers
    Atenolol, LabetalolATV/c, ATV/r, DRV/c, DRV/r↑ beta-blockers possibleNo dose adjustment needed
    Bisoprolol, Carvedilol, Metoprolol, NebivololATV/c, ATV/r, DRV/c, DRV/r↑ beta-blockers possibleMay need to decrease beta-blocker dose; adjust dose based on clinical response.

    Consider using beta-blockers that are not metabolized by CYP2D6 enzymes (e.g., atenolol, labetalol, nadolol).
    Calcium Channel Blockers
    Amlodipine, Felodipine, Nifedipine, VerapamilATV/c, ATV/r, DRV/c, DRV/r↑ CCB possibleTitrate CCB dose and monitor closely. ECG monitoring is recommended when CCB is used with ATV.
    Amlodipine, Felodipine, Nifedipine, VerapamilATV/c, ATV/r, DRV/c, DRV/r↑ CCB possibleTitrate CCB dose and monitor closely. ECG monitoring is recommended when CCB is used with ATV.
    DiltiazemATV/c, ATV/rUnboosted ATV ↑ diltiazem AUC 125%

    Greater ↑ of diltiazem AUC is likely with ATV/c or ATV/r
    Decrease diltiazem dose by at least 50%. If starting diltiazem, start with the lowest dose and titrate according to clinical response and adverse events. ECG monitoring is recommended.
    DRV/c, DRV/r↑ diltiazem possibleTitrate diltiazem dose according to clinical response and adverse events.
    Cardiac—Other
    BosentanATV/c, ATV/r, DRV/c, DRV/rWith LPV/r
    • ↑ bosentan 48-fold (Day 4) and ↑ 5-fold (Day 10)

    With other PI
    ↑ bosentan expected
    With ATV (unboosted)
    ↓ ATV expected
    Do not coadminister bosentan and unboosted ATV.
    In Patients on a PI (Other than Unboosted ATV) >10 Days
    • Start bosentan at 62.5 mg once daily or every other day

    In Patients on Bosentan Who Require a PI (Other Than Unboosted ATV)
    • Stop bosentan ≥36 hours before PI initiation and restart bosentan 10 days after PI initiation at 62.5 mg once daily or every other day.

    When Switching Between COBI and RTV
    • Maintain the same bosentan dose.

    EplerenoneATV/c, ATV/r, DRV/c, DRV/r↑ eplerenone expectedContraindicated.
    IvabradineATV/c, ATV/r, DRV/c, DRV/r↑ ranolazine expectedContraindicated.
    MavacamtenATV/c, ATV/r, DRV/c, DRV/r↑ mavacamten expectedContraindicated.
    RanolazineATV/c, ATV/r, DRV/c, DRV/r↑ ranolazine possibleContraindicated.
    Corticosteroids
    Beclomethasone
    Inhaled or intranasal
    DRV/r↔ 17-BMP (active metabolite) AUC
    RTV 100 mg twice daily ↑ 17-BMP AUC 2-fold
    No dose adjustment needed.
    All PIs except DRV/r↔ 17-BMP expectedNo dose adjustment needed.
    Budesonide, Ciclesonide, Fluticasone, Mometasone
    Inhaled or intranasal
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible
    RTV 100 mg twice daily ↑ fluticasone AUC 350-fold
    Do not coadminister unless the potential benefits of inhaled or intranasal corticosteroid outweigh the risks of adverse events associated with corticosteroids. Coadministration can result in adrenal insufficiency and Cushing’s syndrome. Consider alternative inhaled/intranasal corticosteroid (e.g., beclomethasone).
    Betamethasone, Budesonide
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible

    ↓ PI possible
    Do not coadminister unless the potential benefits of systemic corticosteroid outweigh the risks of adverse events associated with systemic corticosteroids. Coadministration can result in adrenal insufficiency and Cushing’s syndrome.
    Dexamethasone
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids possible
    ↓ PI possible
    Consider alternative corticosteroid for long-term use. If coadministration is necessary, monitor virologic response to ART.
    Prednisone, Prednisolone
    Systemic
    ATV/c, ATV/r, DRV/c, DRV/r↑ prednisolone possibleCoadministration may be considered if the potential benefits outweigh the risks of adverse events associated with systemic corticosteroids. If coadministered, monitor for adrenal insufficiency, Cushing’s syndrome, and other corticosteroid-related adverse events.
    Betamethasone, Methylprednisolone, Triamcinolone
    Local injections, including intra-articular, epidural, or intra-orbital
    ATV/c, ATV/r, DRV/c, DRV/r↑ glucocorticoids expectedDo not coadminister. Coadministration can result in adrenal insufficiency and Cushing’s syndrome.
    Glucose-Lowering
    CanagliflozinATV/c, DRV/c↔ canagliflozinNo dose adjustment needed.
    ATV/r, DRV/r↓ canagliflozin expectedIf a patient is already tolerating canagliflozin 100 mg daily, increase canagliflozin dose to 200 mg daily.
    If a patient is already tolerating canagliflozin 200 mg daily and requires additional glycemic control, management strategy is based on renal function.
    In Patients with eGFR ≥60 mL/min/1.73 m2
    • Canagliflozin dose may be increased to 300 mg daily.

    In Patients with eGFR <60 mL/min/1.73 m2
    • Consider adding another antihyperglycemic agent.
    SaxagliptinAll PIsATV/c, ATV/r, DRV/c, DRV/r↑ saxagliptin expectedLimit saxagliptin dose to 2.5 mg once daily.
    Dapagliflozin/SaxagliptinAll PIsATV/c, ATV/r, DRV/c, DRV/r↑ saxagliptin expectedDo not coadminister. Dapagliflozin is only available as a coformulated drug that contains 5 mg of saxagliptin. When coadministered with EVG/c, the dose of saxagliptin should not exceed 2.5 mg once daily; thus, this combination is not recommended.
    Herbal Products
    St. John’s WortATV/c, ATV/r, DRV/c, DRV/r↓ PI expectedContraindicated.
    Hormonal Therapies—Contraceptives
    Injectable Contraceptives
    Depot MPA
    ATV/c, ATV/r, DRV/c, DRV/r↔ expectedNo dose adjustment needed
    Oral Contraceptives
    (e.g., desogestrel, drospirenone, ethinyl estradiol, levonorgestrel, norgestimate, norethindrone)
    ATV/cDrosperinone AUC ↑ 130%
    Ethinyl estradiol AUC ↓ 22%
    Contraindicated with drospirenone-containing hormonal contraceptive due to potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    ↔ ethinyl estradiol AUC and Cmin ↓ 25%
    ↔ levonorgestrel
    No dose adjustment needed.
    ATV/rEthinyl estradiol AUC ↓ 19% and Cmin ↓ 37%
    Norgestimate AUC ↑ 85%
    Norethindrone AUC ↑ 51% and Cmin ↑ 67%
    Oral contraceptive should contain at least 35 mcg of ethinyl estradiol.c
    ↑ drospirenone expected

    ↔ estetrol
    Clinical monitoring is recommended due to the potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    DRV/cDrospirenone AUC ↑ 58%
    Ethinyl estradiol AUC ↓ 30%
    Clinical monitoring is recommended due to the potential for hyperkalemia. Use alternative ARV or contraceptive methods.
    DRV/rEthinyl estradiol AUC ↓ 44% and Cmin ↓ 62%
    Norethindrone AUC ↓ 14% and Cmin ↓ 30%
    When Used for Contraception

    • Consider alternative ARV or contraceptive methods. If combined, consider using an oral contraceptive with at least 35 mcg of ethinyl estradiol.


    When Used for Other Clinical Indications (e.g., Acne, Menstrual Cycle Regulation)

    • Monitor for clinical effectiveness of hormonal therapy.

    Subdermal Implant Contraceptives
    (e.g., etonogestrel, levonorgestrel)
    ATV/c, ATV/r, DRV/c, DRV/r↑ etonogestrel, levonorgestrel expectedNo dose adjustment needed.
    Transdermal Contraceptives
    (e.g., ethinyl estradiol/norelgestromin, ethinyl estradiol/levonorgestrel)
    ATV/c, ATV/r, DRV/c, DRV/r↓ ethinyl estradiol possible with ritonavir

    ↑ ethinyl estradiol possible with cobicistat

    ↑ norelgestromin, levonorgestrel possible
    No dose adjustment needed.
    Vaginal Ring Contraceptives
    (e.g., etonogestrel/ethinyl estradiol, segesterone/ethinyl estradiol)
    ATV/rEthinyl estradiol AUC ↓ 26%

    Etonogestrel AUC ↑ 79%
    No dose adjustment needed.
    ATV/c, DRV/c, DRV/r↓ ethinyl estradiol possible with ritonavir

    ↑ ethinyl estradiol possible with cobicistat
    Emergency Contraceptives
    Levonorgestrel (oral)
    ATV/c, ATV/r, DRV/c, DRV/r↑ levonorgestrel expectedNo dose adjustment needed.
    Hormonal Therapies—Miscellaneous
    5-Alpha Reductase Inhibitors
    (e.g., dutasteride, finasteride)
    ATV/c, ATV/r, DRV/c, DRV/r↑ dutasteride possible

    ↑ finasteride possible
    Adjust dutasteride dose as needed based on clinical effects. No dose adjustment needed for finasteride.
    Hormonal Therapies—MiscellaneousAll PIs↔ goserelin, leuprolide acetate, and spironolactone expectedNo dose adjustment needed.
    EstradiolATV/c, DRV/c↓ or ↑ estradiol possibleAdjust estradiol dose as needed based on clinical effects.
    ATV/r, DRV/r↓ estradiol possible
    Goserelin, Leuprolide Acetate, SpironolactoneATV/c, ATV/r, DRV/c, DRV/r↔ goserelin, leuprolide acetate, and spironolactone expectedNo dose adjustment needed
    Menopausal Hormone Replacement Therapy
    (e.g., conjugated estrogens, drospirenone, estradiol, MPA, progesterone)
    ATV/c, ATV/r, DRV/c, DRV/r↓ or ↑ estrogen possible with estradiol or conjugated estrogen (equine and synthetic)Adjust estrogen dose as needed based on clinical effects.
    ATV/c, ATV/r, DRV/c, DRV/r↑ drospirenone possible

    ↑ MPA

    ↑ micronized progesterone

    See the Hormonal Therapies—Contraceptives section for other progestin-PI interactions.
    Adjust progestin/progesterone dose as needed based on clinical effects. Drospirenone is not contraindicated with ATV/c products because it is prescribed at a lower dose for menopausal HRT than products used for hormonal contraceptives.
    TestosteroneATV/c, ATV/r, DRV/c, DRV/r↑ testosterone possibleAdjust testosterone dose as needed based on clinical effects.
    Immunosuppressants
    Cyclosporine, Sirolimus, TacrolimusATV/c, ATV/r, DRV/c, DRV/r↑ immunosuppressant expectedInitiate with an adjusted dose of immunosuppressant to account for potential increased concentrations of the immunosuppressant and monitor for immunosuppressant-related adverse events. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with a specialist as necessary.
    EverolimusDRV/c, DRV/rDRV/c, DRV/rDo not coadminister.
    ATV/c, ATV/r↑ immunosuppressant expectedInitiate with an adjusted dose of immunosuppressant to account for potential increased concentrations of the immunosuppressant and monitor for immunosuppressant-related adverse events. Therapeutic drug monitoring of immunosuppressant is recommended. Consult with a specialist as necessary.
    Lipid-Modifying
    AtorvastatinATV/r↑ atorvastatin possibleAdminister the lowest effective atorvastatin dose while monitoring for adverse events.
    ATV/cAtorvastatin AUC ↑ 9.2-fold and Cmax ↑ 18.9-foldDo not coadminister.
    DRV/cAtorvastatin AUC ↑ 3.9-fold and Cmax ↑ 4.2-foldAdminister the lowest effective atorvastatin dose while monitoring for adverse events. Do not exceed 20 mg atorvastatin daily.
    DRV/rDRV/r plus atorvastatin 10 mg similar to atorvastatin 40 mg administered aloneAdminister the lowest effective atorvastatin dose while monitoring for adverse events. Do not exceed 20 mg atorvastatin daily.
    FluvastatinATV/c, DRV/c↑ fluvastatin expectedAdminister the lowest effective fluvastatin dose while monitoring for adverse events.
    ATV/r, DRV/r↑ or ↓ fluvastatin possible
    LomitapideATV/c, ATV/r, DRV/c, DRV/r↑ lomitapide expectedContraindicated.
    LovastatinATV/c, ATV/r, DRV/c, DRV/rSignificant ↑ lovastatin expectedContraindicated.
    PitavastatinATV/c, ATV/r, DRV/c, DRV/rWith Unboosted ATV
    • ↑ pitavastatin AUC 31% and Cmax ↑ 60%
    • ↔ ATV

    With DRV/r
    • ↓ pitavastatin AUC 26%
    • ↔ DRV/r

    With LPV/r
    • ↓ pitavastatin AUC 20%
    • ↔ LPV
    No dose adjustment needed.
    PravastatinATV/c, DRV/cNo dataAdminister the lowest effective pravastatin dose while monitoring for adverse events.
    DRV/c, DRV/rWith DRV/r
    • Pravastatin AUC ↑ 81% following single dose of pravastatin
    • Pravastatin AUC ↑ 23% at steady state
    Administer the lowest effective pravastatin dose while monitoring for adverse events.
    PravastatinATV/c, ATV/rNo dataAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 10 mg daily.
    DRV/c, DRV/rWith DRV/r

    • Pravastatin AUC ↑ 81% following single dose of pravastatin

    • Pravastatin AUC ↑ 23% at steady state
    Administer the lowest effective pravastatin dose while monitoring for adverse events.
    RosuvastatinATV/rRosuvastatin AUC ↑ 3-fold and Cmax ↑ 7-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 10 mg daily.
    ATV/cRosuvastatin AUC ↑ 3.4-fold and Cmax ↑ 10.6-fold
    DRV/cRosuvastatin AUC ↑ 1.9-fold and Cmax ↑ 3.8-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events. Do not exceed rosuvastatin 20 mg daily.
    DRV/rRosuvastatin AUC ↑ 48% and Cmax↑ 2.4-foldAdminister the lowest effective rosuvastatin dose while monitoring for adverse events.
    SimvastatinATV/c, ATV/r, DRV/c, DRV/rSignificant ↑ simvastatin expectedContraindicated.
    Narcotics and Treatment for Opioid Dependence
    Buprenorphine
    Sublingual, buccal, or implant
    ATV/rBuprenorphine AUC ↑ 66%
    Norbuprenorphine (active metabolite) AUC ↑ 105%
    Monitor for sedation and other signs or symptoms of overmedication. Buprenorphine dose reduction may be necessary. It may be necessary to remove the implant and treat with a formulation that permits dose adjustments.
    DRV/r↔ buprenorphine
    Norbuprenorphine (active metabolite) AUC ↑ 46% and Cmin ↑ 71%
    No dose adjustment needed. Monitor for buprenorphine-related adverse events. When transferring buprenorphine from transmucosal delivery to implantation, monitor to ensure buprenorphine effect is adequate and not excessive
    ATV/c, DRV/c↑ buprenorphine possibleTitrate buprenorphine dose using the lowest initial dose. Dose adjustment of buprenorphine may be needed. It may be necessary to remove implant and treat with a formulation that permits dose adjustments. Monitor for buprenorphine-related adverse events.
    FentanylATV/c, ATV/r, DRV/c, DRV/r↑ fentanyl possibleMonitor for fentanyl-related adverse events, including potentially fatal respiratory depression
    LofexidineATV/c, ATV/r, DRV/c, DRV/r↑ lofexidine possibleMonitor for lofexidine-related adverse events, including symptoms of orthostasis and bradycardia.
    MethadoneATV/c, DRV/cNo dataTitrate methadone dose using the lowest feasible initial dose. Dose adjustment of methadone may be needed. Monitor for methadone-related adverse events.
    ATV/r, DRV/rATV/r and DRV/r ↓ R-methadoned AUC 16% to 18%
    LPV/r ↓ methadone AUC 26% to 53%
    Opioid withdrawal is unlikely, but may occur. Monitor for opioid withdrawal and increase methadone dose as clinically indicated.
    OxycodoneATV/c, ATV/r, DRV/c, DRV/rLPV/r ↑ oxycodone AUC 2.6-fold
    Other PIs: ↑ oxycodone expected
    Monitor for opioid-related adverse events, including potentially fatal respiratory depression. Oxycodone dose reduction may be necessary.
    TramadolATV/c, ATV/r, DRV/c, DRV/r↑ tramadol expected
    ↓ M1 (active metabolite) possible
    Tramadol dose adjustments may be necessary. Monitor for clinical response and tramadol-related adverse events.
    PDE5 Inhibitors
    AvanafilATV/c, ATV/r, DRV/c, DRV/rRTV 600 mg twice daily (for 5 days) ↑ avanafil AUC 13-fold and ↑ Cmax 2.4-foldDo not coadminister.
    SildenafilATV/c, ATV/r, DRV/c, DRV/rDRV/r plus sildenafil 25 mg similar to sildenafil 100 mg alone

    RTV 500 mg twice daily ↑ sildenafil AUC 1,000%
    For Treatment of Erectile Dysfunction
    • Start with sildenafil 25 mg every 48 hours and monitor for adverse events of sildenafil.

    Contraindicated for treatment of PAH.
    TadalafilATV/c, ATV/r, DRV/c, DRV/rRTV 200 mg twice daily ↑ tadalafil AUC 124%RTV 200 mg twice daily ↑ tadalafil AUC 124%
    • Start with tadalafil 5 mg and do not exceed a single dose of tadalafil 10 mg every 72 hours. Monitor for adverse events of tadalafil.

    For Treatment of PAH
    In Patients on a PI >7 Days
    • Start with tadalafil 20 mg once daily and increase to tadalafil 40 mg once daily based on tolerability.

    In Patients on Tadalafil who Require a PI
    • Stop tadalafil ≥24 hours before PI initiation. Seven days after PI initiation, restart tadalafil at 20 mg once daily and increase to tadalafil 40 mg once daily based on tolerability.

    In Patients Switching between COBI and RTV
    • Maintain tadalafil dose.

    For Treatment of Benign Prostatic Hyperplasia
    • Maximum recommended daily dose is tadalafil 2.5 mg per day.
    VardenafilATV/c, ATV/r, DRV/c, DRV/rRTV 600 mg twice daily ↑ vardenafil AUC 49-foldStart with vardenafil 2.5 mg every 72 hours and monitor for adverse events of vardenafil.
    Sedative/Hypnotics
    Benzodiazepines
    Alprazolam, Clonazepam, DiazepamATV/c, ATV/r, DRV/c, DRV/r↑ benzodiazepine possible
    RTV 200 mg twice daily (for 2 days) ↑ alprazolam half-life 222% and ↑ AUC 248%
    Consider alternative benzodiazepines, such as lorazepam, oxazepam, or temazepam.
    Lorazepam, Oxazepam, TemazepamATV/c, ATV/r, DRV/c, DRV/rNo dataThese benzodiazepines are metabolized via non-CYP450 pathways and therefore have less interaction potential than other benzodiazepines.
    MidazolamATV/c, ATV/r, DRV/c, DRV/r↑ midazolam expectedOral midazolam is contraindicated with PIs.
    Parenteral midazolam can be used with caution when given in a monitored situation with appropriate medical management available in case of respiratory sedation and/or prolonged sedation. Consider dose reduction, especially if more than a single dose of midazolam is administered.
    TriazolamATV/c, ATV/r, DRV/c, DRV/r↑ triazolam expected
    RTV 200 mg twice daily ↑ triazolam half-life 1,200% and ↑ AUC 2,000%
    Contraindicated.
    Orexin Receptor Antagonist
    Daridorexant, Lemborexant, SuvorexantATV/c, ATV/r, DRV/c, DRV/r↑ daridorexant, lemborexant, suvorexant expectedDo not coadminister.
    Other Sedatives
    EszopicloneATV/c, ATV/r, DRV/c, DRV/r↑ eszopiclone possibleStart with lowest dose and increase to a maximum of 2 mg daily; monitor for eszopiclone-related adverse events.
    ZolpidemATV/c, ATV/r, DRV/c, DRV/r↑ zolpidem possibleInitiate zolpidem at a low dose and monitor for zolpidem-related adverse events. Dose reduction may be necessary.
    Miscellaneous
    CalcifediolATV/c, ATV/r, DRV/c, DRV/r↑ calcifediol possibleDose adjustment of calcifediol may be required, and serum 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations should be closely monitored.
    CisaprideATV/c, ATV/r, DRV/c, DRV/r↑ cisapride expectedContraindicated.
    ColchicineATV/c, ATV/r, DRV/c, DRV/rRTV 100 mg twice daily ↑ colchicine AUC 296% and Cmax ↑ 184%

    Significant ↑ colchicine expected with all PIs, with or without COBI or RTV
    For Treatment of Gout Flares
    • Administer a single dose of colchicine 0.6 mg, followed by colchicine 0.3 mg 1 hour later. Do not repeat dose for at least 3 days

    For Prophylaxis of Gout Flares
    • If original dose was colchicine 0.6 mg twice daily, decrease to colchicine 0.3 mg once daily. If dose was 0.6 mg once daily, decrease to 0.3 mg every other day.

    For Treatment of Familial Mediterranean Fever
    • Do not exceed colchicine 0.6 mg once daily or colchicine 0.3 mg twice daily.

    Contraindicated in patients with hepatic (Child-Pugh Score A, B or C) or renal impairment (CrCl <60 mL/min).
    DronabinolATV/c, ATV/r, DRV/c, DRV/r↑ dronabinol possibleMonitor for dronabinol-related adverse events.
    EluxadolineATV/c, ATV/r, DRV/c, DRV/r↑ eluxadoline expectedAdminister eluxadoline at a dose of 75 mg twice daily and monitor for eluxadoline-related adverse events.
    Ergot DerivativesATV/c, ATV/r, DRV/c, DRV/r↑ dihydroergotamine, ergotamine, and methylergonovine expectedContraindicated.
    FlibanserinATV/c, ATV/r, DRV/c, DRV/r↑ flibanserin expectedContraindicated.
    a DHA is an active metabolite of artemether and artesunate.

    bThe following products contain no more than 30 mcg of ethinyl estradiol combined with norethindrone or norgestimate: Lo Minastrin Fe; Lo Loestrin Fe; Loestrin 1/20, 1.5/30; Loestrin Fe 1/20, 1.5/30; Loestrin 24 Fe; Minastrin 24 Fe; Ortho Tri-Cyclen Lo. Generic formulations also may be available.


    cThe following products contain at least 35 mcg of ethinyl estradiol combined with norethindrone or norgestimate: Brevicon; Femcon Fe; Modicon; Norinyl 1/35; Ortho-Cyclen; Ortho-‍Novum 1/35, 7/7/7; Ortho Tri-Cyclen; Ovcon 35; Tri-Norinyl. Generic formulations also may be available.


    dR-methadone is the active form of methadone.

    Key to Symbols

    ↑ = increase
    ↓ = decrease
    ↔ = less than 20% change in AUC

    Key: 17-BMP = beclomethasone 17-monopropionate; ALT = alanine aminotransferase; ART = antiretroviral therapy; ARV = antiretroviral; AST = aspartate aminotransferase; ATV = atazanavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; CCB = calcium channel blocker; CNS = central nervous system; COBI = cobicistat; CrCl = creatinine clearance; CMV = cytomegalovirus; CV = cardiovascular; CYP = cytochrome P; DHA = dihydroartemisinin; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DVT = deep vein thrombosis; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate; EVG/c = elvitegravir/cobicistat; GI = gastrointestinal; H2RA = H2 receptor antagonist; HCV = hepatitis C virus; HRT = hormone replacement therapy; INR = international normalized ratio; LPV = lopinavir; LPV/r = lopinavir/ritonavir; MPA = medroxyprogesterone acetate; OATP = organic anion-transporting polypeptide; PAH = pulmonary arterial hypertension; PDE5 = phosphodiesterase type 5; PE = pulmonary embolism; PI = protease inhibitor; PI/c = protease inhibitor/cobicistat; PI/r = protease inhibitor/ritonavir; PK = pharmacokinetic; PPI = proton pump inhibitor; PTH = parathyroid hormone; QTc = QT corrected for heart rate; RTV = ritonavir; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; TDF = tenofovir disoproxil fumarate; VPA = valproic acid
    Scroll to Top